Catherine M. Sherwin

Catherine M. Sherwin, PhD, BSc (Hons), BN, MSCI

Languages spoken: English

Academic Information

Departments Adjunct - Pediatrics

Divisions: Clinical Pharmacology

Academic Office Information

catherine.sherwin@hsc.utah.edu

Board Certification

  • American Board of Clinical Pharmacology

Dr. Catherine Sherwin, a Professor, and Vice�chair for Research at the Department of Pediatrics, Wright State University Boonshoft School of Medicine and Dayton Children's Hospital. Dr. Sherwin was formerly an Associate Professor, Chief of the Division of Clinical Pharmacology and Director of the Utah Pediatric Clinical Pharmacology Fellowship Program, Department of Pediatrics, University of Utah School of Medicine. She still holds an Adjunct position in the Department of Pharmacotherapy, College of Pharmacy, Univeraoiut of Utah. She earned her Ph.D. at the University of Otago, Dunedin School of Medicine, New Zealand in Paediatric Clinical Pharmacology in 2007. She then completed one year of postdoctoral training in

the Women’s and Children’s Health in Dunedin and then a two�year NIH T32 Fellowship training program in the Divisions of Clinical Pharmacology and Division of Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center. She received board certification from the American Board of Clinical Pharmacology in 2011. Dr. Sherwin became a Fellow (FCP) of the Americal College of Clinical Pharmacology (ACCP) in 2014 and was voted to the Board of Regents for ACCP in 2018.



Dr. Sherwin has expertise and experience in the development of quantitative pharmacometric (PK/PD/PG) models in special populations, including pediatric and neonatal patients. Dr. Sherwin’s areas of clinical research focus are clinical pharmacology/toxicology and pharmacometrics within the area of pediatrics and maternal health, and specifically the juncture of the two: neonatology and pregnancy. She is highly committed to understanding how the physical size and physiological based information can be systematically utilized to understand the

inherent pharmacology. She has a combination of skill sets that are in high demand; having been trained in pediatric clinical pharmacology and pharmacometrics. The natural overlap between these two areas of expertise complement one another and allow Dr. Sherwin to provide a unique level of technical depth and research insight to pediatric studies. Her research involves understanding the pharmacology of drugs in neonatal and pediatric populations which has allowed her to become an expert in the techniques of pharmacometric modeling and scaling which are crucial for pediatric clinical trials. Dr. Sherwin’s research has a highly clinical focus and combines the utility and innovation of modeling and simulation to provide research answers to real clinical questions. Dr. Sherwin’s research and expertise are also in optimal sample design and clinical trial simulation. Dr. Sherwin has specific interests and expertise with numerous drug classes including antibiotics, immunosuppressants, antiepileptics, anesthetic agents and opioids.

Research Statement

Dr. Catherine Sherwin is currently an Associate Professor and Chief of the Division of Clinical Pharmacology, Department of Pediatrics, University of Utah School of Medicine. She earned her PhD at the University of Otago, Dunedin School of Medicine, New Zealand in Paediatric Clinical Pharmacology in 2007. She then completed one year of Postdoctoral training in the Women’s and Children’s Health in Dunedin and then a two year T32 Fellowship training program in the Divisions of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center. She received board certification from the American Board of Clinical Pharmacology in 2011. Dr. Sherwin has expertise and experience in the development of quantitative pharmacometric (PK/PD/PG) models in special populations including pediatric and neonatal patients.

Dr. Sherwin’s areas of clinical research focus are clinical pharmacology/toxicology and pharmacometrics within the area of pediatrics and maternal health, and specifically the juncture of the two: neonatology and pregnancy. She is highly committed to understanding how physical size and physiological based information can be systematically utilized understand the inherent pharmacology. She has a combination of skill sets that are in high demand; having been trained in pediatric clinical pharmacology and pharmacometrics. The natural overlap between these two areas of expertise complement one another and allow Dr. Sherwin to provide a unique level of technical depth and research insight to pediatric studies. Dr. Sherwin’s research has a highly clinical focus and combines the utility and innovation of modeling and simulation to provide research answers to real clinical questions.

Education History

Certification Meadowbank TAFE College, Concord General Repatriation Hospital
 Certificate
Undergraduate Lincoln University and Research performed at Agri-Quality Animal Health Laboratory
 BS
Other Training Christchurch School of Medicine and Health Sciences, Canterbury Health Laboratory
Other Training Otago School of Medicine and Health Sciences, Department Pharmacology & Toxicology
Doctoral Training University of Otago, Dunedin School of Medicine, Department of Women¿s and Children¿s Health
 PhD
Postdoctoral Fellowship University of Otago, Dunedin School of Medicine, Department of Women¿s and Children¿s Health
 Postdoctoral Clinical Research Fellow
Postdoctoral Fellowship Cincinnati Children's Hospital Medical Center, Divisions of Clinical Pharmacology and Rheumatology
 Postdoctoral Clinical Research Fellow
Graduate Training University of Utah
 MSc

Selected Publications

Journal Article

  1. Rahimi R, Heidari-Soureshjani S, Sherwin CMT, Kasiri K, Rahimian (2024). The Association between Gallstone Disease and Incidence of Cardiovascular Disease: A Systematic Review and Meta-Analysis. Reviews on recent clinical trials,
  2. Chhibber A, Watanabe AH, Jacobs H, Kharat A, Syeed SM, Sherwin CM, Chaiyakunapruk N, Biskupiak J, Yellepeddi VK, Brixner D, Young D (2024). Potential of pharmacogenetics in minimizing drug therapy problems in cystic fibrosis. Journal of cystic fibrosis, 23(5), 1010-1019.
  3. Wu Y, Allegaert K, Flint RB, Goulooze SC, Välitalo PAJ, de Hoog M, Mulla H, Sherwin CMT, Simons SHP, Krekels EHJ, Knibbe CAJ, Völler (2024). When will the Glomerular Filtration Rate in Former Preterm Neonates Catch up with Their Term Peers?. Pharmaceutical research, 41(4), 637-649.
  4. Holford N, O'Hanlon CJ, Allegaert K, Anderson B, Falcão A, Simon N, Lo YL, Thomson AH, Sherwin CM, Jacqz-Aigrain E, Llanos-Paez C, Hennig S, Mockus L, Kirkpatrick (2024). A physiological approach to renal clearance: From premature neonates to adults. British journal of clinical pharmacology, 90(4), 1066-1080.
  5. Rahimi R, Masoumi S, Badali A, Jafari N, Heidari-Soureshjani S, Sherwin CM (2024). Association Between Gallstone Disease and Risk of Mortality of Cardiovascular Disease and Cancer: A Systematic Review and Meta-Analysis. Cardiovascular & hematological disorders drug targets, 24(1), 47-58.
  6. Rahimi-Dehkordi N, Heidari-Soureshjani S, Sherwin CM (2024). The Effects and Safety of Silymarin on ß-thalassemia in Children and Adolescents: A Systematic Review based on Clinical Trial Studies. Reviews on recent clinical trials, 19(4), 242-255.
  7. Khaghani A, Kasiri K, Heidari-Soureshjani S, Sherwin CMT, Mardani-Nafchi (2024). A Systematic Review and Meta-analysis of the Relationship between Statin Intake and Esophageal Cancer. Anti-cancer agents in medicinal chemistry, 24(14), 1029-1037.
  8. Jivad N, Heidari-Soureshjani S, Bagheri H, Sherwin CMT, Rostamian (2024). Anti-seizure Effects and Mechanisms of Berberine: A Systematic Review. Current pharmaceutical biotechnology, 25(17), 2253-2265.
  9. Ghahfarrokhi SH, Heidari-Soureshjani S, Sherwin CMT, Azadegan-Dehkordi (2024). Efficacy and Mechanisms of Silybum Marianum, Silymarin, and Silibinin on Rheumatoid Arthritis and Osteoarthritis Symptoms: A Systematic Review. Current rheumatology reviews, 20(4), 414-425.
  10. Emami E,Sherwin CMT,Heidari-Soureshjani (2024). Effect of Probiotics on Urinary Tract Infections in Children: A Systematic Review and Meta-Analysis. Current reviews in clinical and experimental pharmacology, 19(1), 111-121.
  11. Han X,Vollmer D,Yan X,Zhang Y,Zang M,Zhang C,Sherwin CM,Enioutina E (2024). Immunomodulatory Effects of Modified Colostrum, Whey, and Their Combination With Other Natural Products: Effects on Natural Killer Cells. Current therapeutic research, clinical and experimental, 101,
  12. Maglalang PD,Sinha J,Zimmerman K,McCann S,Edginton A,Hornik CP,Hornik CD,Muller WJ,Al-Uzri A,Meyer M,Chen JY,Anand R,Perrin EM,Gonzalez D,Delmore P,Dixit S,Shimizu J,Shakespear K,Salman Y,Rosen P,Perez R,Narus JA,Alger F,Sherwin C,Spigarelli M,Talbert J,Mariconti A,Bernhardt J,Laughon M,Wiseheart M,Perry J,Michael A,Comings J,Brown K,Konow C,Poff S,Kernen K,Sullivan J,Ann DP,Howard L,Hart M,Hansberry D,James L,Parsons A,Petersen L,Tasi C,Adams R,Goldblatt E,Vitou B,Lemon E,Speicher D,Toltzis P,Borges A,Thoma K,Rathore M,Rumantir M,Finkelstein Y,Lang E,Shankar K,Deville J,Moore A,Kost B,Sokol G,Poindexter B,Denne S,Baez A,Wrenn S,Milleson C,Tiedge H,Baisden N,Jefferson G,Watt K,Kirby C,Gerhardt B,DePaoli B,Arnold P,Terrell T,Mottes T,Goldstein S,Bradley G,Ieradi S,Murchison B,Tuttle A,Pohl D,Lacaze T,Zemek R,McMillan H,Van K,Steinbeiss M,Sierra Y,Rutebemberwa A,Ralston K,Malone K,Halstenson G,Dix M,DiDomenico D,Deschenes J,Mourani P,Goldenberg N,Lague (2024). Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population. Clinical pharmacokinetics, 63(6), 885-899.
  13. Oyebanji OA, Brewer C, Bayless S, Schmeusser B, Corbin DA, Sulentic CEW, Sherwin CMT, Chen Y, Rapp CM, Cates EE, Long Y, Travers JB, Rohan C (2023). Topical photodynamic therapy generates bioactive microvesicle particles: evidence for a novel pathway involved in immunosuppressive effects. The Journal of investigative dermatology,
  14. Zhang T, Smit C, Sherwin CMT, Knibbe CAJ, Krekels EH (2023). Vancomycin Clearance in Obese Adults is not Predictive of Clearance in Obese Adolescents. Clinical pharmacokinetics,
  15. Zhang T,Smit C,Sherwin CMT,Knibbe CAJ,Krekels EH (2023). Vancomycin Clearance in Obese Adults is not Predictive of Clearance in Obese Adolescents. Clinical pharmacokinetics,
  16. Emami E, Heidari-Soureshjani S, Oroojeni Mohammadjavad A, Sherwin C (2023). Obesity and the Risk of Developing Kidney Stones: A Systematic Review and Meta-analysis. Iranian journal of kidney diseases, 1(2), 63-72.
  17. Haslund-Krog S, Barry JM, Birnbaum AK, Dalhoff K, Brink Henriksen T, Sherwin CMT, Avachat C, Poulsen S, Christensen U, Remmel RP, Wilkins D, van den Anker JN, Holst (2023). Pharmacokinetics and safety of prolonged paracetamol treatment in neonates: An interventional cohort study. British journal of clinical pharmacology, 89(11), 3421-3431.
  18. Fike CD, Aschner JL, Avachat C, Birnbaum AK, Sherwin CM (2023). Multi-dose enteral L-citrulline administration in premature infants at risk of developing pulmonary hypertension associated with bronchopulmonary dysplasia. Journal of perinatology, 44(2), 280-287.
  19. Krepkova LV, Babenko AN, Lemyaseva SV, Saybel OL, Sherwin CM, Enioutina E (2023). Modulation of Hepatic Functions by Chicory (Cichorium intybus L.) Extract: Preclinical Study in Rats. Pharmaceuticals (Basel, Switzerland), 16(10),
  20. Rostamian S, Heidari-Soureshjani S, Sherwin CM (2023). The Therapeutic Effect of Silymarin and Silibinin on Depression and Anxiety Disorders and Possible Mechanism in the Brain: A Systematic Review. Central nervous system agents in medicinal chemistry, 23(2), 86-94.
  21. Savadjani SA, Sherwin CM, Heidari-Soureshjani S, Darvishi M, Amiri M (2023). The Role of Vitamin D in Carpal Tunnel Syndrome Risk and Supplementation Outcomes: A Systematic Review. Current rheumatology reviews, 19(4), 439-448.
  22. Krepkova LV,Babenko AN,Lemyaseva SV,Saybel OL,Sherwin CM,Enioutina E (2023). Modulation of Hepatic Functions by Chicory (Cichorium intybus L.) Extract: Preclinical Study in Rats ¿. Pharmaceuticals (Basel, Switzerland), 16(10),
  23. Fike CD,Aschner JL,Avachat C,Birnbaum AK,Sherwin CM (2023). Multi-dose enteral L-citrulline administration in premature infants at risk of developing pulmonary hypertension associated with bronchopulmonary dysplasia. Journal of perinatology,
  24. Mohammadi-Dashtaki R,Heidari-Soureshjani S,Sherwin CM (2023). The Effect of Inhalation Aromatherapy on Patients with Cardiovascular Disease Seeking Pain Relief: A Systematic Review and Meta-analysis. Current drug therapy, 18(3), 262-270.
  25. McGlone CL, Christian L, Schmeusser B, Liu L, Chalfant CE, Stephensen DJ, Sherwin CM, Rapp CM, Sattouf Z, Rohan CA, Morris C, Chen Y, Travers J (2022). Evidence for Systemic Reactive Oxygen Species in UVB-mediated Microvesicle Formation. Photochemistry and photobiology, 98(1), 242-247.
  26. Fike CD, Avachat C, Birnbaum AK, Aschner JL, Sherwin C (2022). Pharmacokinetics of L-Citrulline in Neonates at Risk of Developing Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension. Paediatric drugs, 25(1), 87-96.
  27. Derbalah A, Duffull S, Sherwin CM, Job K, Al-Sallami (2022). Optimal dosing of enoxaparin in overweight and obese children. British journal of clinical pharmacology,
  28. Sherwin CM, Tran NK, Sullivan K, Wead S, Birnbaum AK, Avachat C, Kagan RJ, Healy D (2022). Exploring the past to inform the future to optimize the pharmacokinetics of vancomycin in children with severe burn injuries. Journal of burn care & research,
  29. McKnite AM,Job KM,Nelson R,Sherwin CMT,Watt KM,Brewer S (2022). Medication based machine learning to identify subpopulations of pediatric hemodialysis patients in an electronic health record database. Informatics in medicine unlocked, 34,
  30. Gerhart JG,Carreño FO,Ford JL,Edginton A,Perrin EM,Watt KM,Muller WJ,Atz AM,Al-Uzri A,Delmore P,Gonzalez D,Benjamin DK,Hornik C,Zimmerman K,Kennel P,Beci R,Dang Hornik C,Kearns GL,Laughon M,Paul IM,Sullivan J,Wade K,Delmore P,Taylor-Zapata P,Lee J,Anand R,Sharma G,Simone G,Kaneshige K,Taylor L,Al-Uzri A,Hornik C,Sokol G,Speicher D,Sullivan J,Mourani P,Mendley S,Meyer M,Atkins R,Flynn J,Vaughns J,Sherwin C,Delmore P,Goldstein S,Rathore M,Melloni C,Muller W,Delmore P,Tremoulet A,James L,Mendley S,Blackford M,Atz A,Adu-Darko M,Mourani P,Watt K,Hornik C,Al-Uzri A,Sullivan J,Laughon M,Brian Smith P,Watt K,Cheifetz I,Atz A,Bhatt-Mehta V,Fernandez A,Lowry (2022). Use of physiologically-based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity. CPT, 11(6), 778-791.
  31. McKnite AM, Job KM, Nelson R, Sherwin CMT, Watt KM, Brewer S (2022). Medication based machine learning to identify subpopulations of pediatric hemodialysis patients in an electronic health record database. Informatics in medicine unlocked, 34,
  32. Emami E, Heidari-Soureshjani S, Sherwin C (2022). Anti-inflammatory response to curcumin supplementation in chronic kidney disease and hemodialysis patients: A systematic review and meta-analysis. Avicenna journal of phytomedicine, 12(6), 576-588.
  33. Krepkova LV, Bortnikova VV, Babenko AN, Mizina PG, Mkhitarov VA, Job KM, Sherwin CM, Enioutina E (2021). Effects of a new thyrotropic drug isolated from Potentilla alba on the male reproductive system of rats and offspring development. BMC complementary medicine and therapies, 21(1), 31.
  34. Maharaj AR, Wu H, Zimmerman KO, Muller WJ, Sullivan JE, Sherwin CMT, Autmizguine J, Rathore MH, Hornik CD, Al-Uzri A, Payne EH, Benjamin DK Jr, Hornik CP, Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee (2021). Pharmacokinetics of Ceftazidime in Children and Adolescents with Obesity. Paediatric drugs, 23(5), 499-513.
  35. Barry JM, Birnbaum AK, Jasin LR, Sherwin C (2021). Maternal Exposure and Neonatal Effects of Drugs of Abuse. Journal of clinical pharmacology, 61 Suppl 2, S142-S155.
  36. Heidari-Soureshjani S,Sherwin CM (2021). Effects of medicinal plants on human hosts and zoonotic helminthic infections: A systematic review. The natural products journal, 11(4), 472-490.
  37. Biltaji, E., Enioutina, E.Y., Yellepeddi, V., Rower, J.E., Sherwin, C.M.T., Ward, R.M., Lemons, R.S., Constance, J.E. (2020). Supportive care medications coinciding with chemotherapy among children with hematologic malignancy. Leuk Lymphoma, 61, 1-12.
  38. Rashid J, Kumar SS, Job KM, Liu X, Fike CD, Sherwin CM (2020). Therapeutic Potential of Citrulline as an Arginine Supplement: A Clinical Pharmacology Review. Paediatric drugs, 22(3), 279-293.
  39. Kumar SS, Liu X, Sherwin CM, Jones B (2020). The Reliability of Histamine Pharmacodynamic Response Phenotype Classification in Children With Allergic Disease. Frontiers in pharmacology, 11, 227.
  40. Illamola SM, Amaeze OU, Krepkova LV, Birnbaum AK, Karanam A, Job KM, Bortnikova VV, Sherwin CMT, Enioutina E (2020). Use of Herbal Medicine by Pregnant Women: What Physicians Need to Know. Frontiers in pharmacology, 10, 1483.
  41. Kumar SS,Liu X,Sherwin CM,Jones B (2020). The Reliability of Histamine Pharmacodynamic Response Phenotype Classification in Children With Allergic Disease. Frontiers in pharmacology, 11,
  42. Kamp J,Olofsen E,Henthorn TK,Van Velzen M,Niesters M,Dahan A,Backman JT,Drover DR,Elkomy MH,Fanta S,Flint RB,Gustafsson LL,Hammer GB,Herd DW,Kalso E,Mathôt RAA,Olkkola K,Peltoniemi M,Persson J,Ramamoorthy C,Saari TI,Sherwin CM (2020). Ketamine Pharmacokinetics: A Systematic Review of the Literature, Meta-analysis, and Population Analysis. Anesthesiology, 1192-1213.
  43. Rower, J.E., Anderson, D.J., Sherwin, C.M., Reilly, C.A., Ballard, P.L., McEvoy, C.T., Wilkins, D.G. (2019). Development and validation of an assay for quantifying budesonide in dried blood spots collected from extremely low gestational age neonates. J Pharm Biomed Anal, 167, 7-14.
  44. Yellepeddi V, Rower J, Liu X, Kumar S, Rashid J, Sherwin CM (2019). State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development. Clinical pharmacokinetics, 58(1), 1-13.
  45. Wang J, Kumar SS, Sherwin CM, Ward R, Baer G, Burckart GJ, Wang Y, Yao L (2019). Renal Clearance in Newborns and Infants: Predictive Performance of Population-Based Modeling for Drug Development. Clinical pharmacology and therapeutics, 105(6), 1462-1470.
  46. Becker SM, Job KM, Lima K, Forbes TJ, Wagstaff J, Tran NK, Sherwin CM, Nelson DS, Johnson MD, Rower J (2019). Prospective study of serum and ionized magnesium pharmacokinetics in the treatment of children with severe acute asthma. European journal of clinical pharmacology, 75(1), 59-66.
  47. Stockmann C, Olson J, Rashid J, Lubsch L, Young DC, Hersh AL, Frymoyer A, Ampofo K, Liu X, Wang Y, Sherwin CMT, Zobell J (2019). An Evaluation of Vancomycin Area Under the Curve Estimation Methods for Children Treated for Acute Pulmonary Exacerbations of Cystic Fibrosis Due to Methicillin-Resistant Staphylococcus aureus. Journal of clinical pharmacology, 59(2), 198-205.
  48. Wang H, Sherwin C, Gobburu JVS, Ivaturi (2019). Population Pharmacokinetic Modeling of Gentamicin in Pediatrics. Journal of clinical pharmacology, 59(12), 1584-1596.
  49. Deng J, Chalhoub NE, Sherwin CM, Li C, Brunner H (2019). Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Seminars in arthritis and rheumatism, 49(2), 251-259.
  50. Liu X, Smits A, Wang Y, Renard M, Wead S, Kagan RJ, Healy DP, De Cock P, Allegaert K, Sherwin CM (2019). Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children. Therapeutic drug monitoring, 41(1), 44-52.
  51. Tak CR, Gunning K, Kim J, Sherwin CM, Ruble JH, Nickman NA, Biskupiak J (2019). The effect of a prescription order requirement for pharmacist-administered vaccination on herpes zoster vaccination rates. Vaccine, 37(4), 631-636.
  52. Radhakrishnan SV, Boyer M, Sherwin CM, Zangari M, Tricot (2019). A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma. Cell transplantation, 28(12), 1624-1631.
  53. Balch A, Wilkes J, Thorell E, Pavia A, Sherwin CMT, Enioutina E (2019). Changing trends in IVIG use in pediatric patients: A retrospective review of practices in a network of major USA pediatric hospitals. International immunopharmacology, 76, 105868.
  54. Tak CR, Biltaji E, Kohlmann W, Maese L, Hainaut P, Villani A, Malkin D, Sherwin CMT, Brixner DI, Schiffman J (2019). Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome. Pediatric blood & cancer, 66(5), e27629.
  55. Krzyzanski W, Cook SF, Wilbaux M, Sherwin CMT, Allegaert K, Vermeulen A, van den Anker J (2019). Population Pharmacokinetic Modeling in the Presence of Missing Time-Dependent Covariates: Impact of Body Weight on Pharmacokinetics of Paracetamol in Neonates. The AAPS journal, 21(4), 68.
  56. Grimsrud KN, Ivanova X, Sherwin CM, Palmieri TL, Tran N (2019). Identification of Cytochrome P450 Polymorphisms in Burn Patients and Impact on Fentanyl Pharmacokinetics: A Pilot Study. Journal of burn care & research, 40(1), 91-96.
  57. Thyagarajan A, Alshehri MSA, Miller KLR, Sherwin CM, Travers JB, Sahu R (2019). Myeloid-Derived Suppressor Cells and Pancreatic Cancer: Implications in Novel Therapeutic Approaches. Cancers, 11(11),
  58. Wagstaff JS, Durrant RJ, Newman MG, Eason R, Ward RM, Sherwin CMT, Enioutina E (2019). Antibiotic Treatment of Suspected and Confirmed Neonatal Sepsis Within 28 Days of Birth: A Retrospective Analysis. Frontiers in pharmacology, 10, 1191.
  59. Tak CR, Kim J, Gunning K, Sherwin CM, Nickman NA, Biskupiak J (2019). Cost-Sharing Requirements for the Herpes Zoster Vaccine in Adults Aged 60. The Journal of pharmacy technology, 35(6), 258-269.
  60. Tak CR,Kim J,Gunning K,Sherwin CM,Nickman NA,Biskupiak J (2019). Cost-Sharing Requirements for the Herpes Zoster Vaccine in Adults Aged 60+. The Journal of pharmacy technology, 35(6), 258-269.
  61. Illamola SM,Amaeze OU,Krepkova LV,Birnbaum AK,Karanam A,Job KM,Bortnikova VV,Sherwin CMT,Enioutina E (2019). Use of herbal medicine by pregnant women: What physicians need to know. Frontiers in pharmacology, 10,
  62. Wagstaff JS,Durrant RJ,Newman MG,Eason R,Ward RM,Sherwin CMT,Enioutina E (2019). Antibiotic treatment of suspected and confirmed neonatal sepsis within 28 days of birth: A retrospective analysis. Frontiers in pharmacology, 10,
  63. Illamola, S.M., Huynh, H.Q., Liu, X., Bhakta, Z.N., Sherwin, C.M., Liou, T.G., Carveth, H., Young, D.C. (2018). Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis. Antimicrob Agents Chemother, 62(10).
  64. Illamola, S.M., Bucci-Rechtweg, C., Costantine, M.M., Tsilou, E., Sherwin, C.M., Zajicek, A. (2018). Inclusion of pregnant and breastfeeding women in research - efforts and initiatives. Br J Clin Pharmacol, 84(2), 215-222.
  65. Illamola SM, Sherwin CM, van Hasselt JG (2018). Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses. Clinical pharmacokinetics, 57(10), 1217-1228.
  66. Linakis MW, Cook SF, Kumar SS, Liu X, Wilkins DG, Gaedigk R, Gaedigk A, Sherwin CM, van den Anker J (2018). Polymorphic Expression of UGT1A9 is Associated with Variable Acetaminophen Glucuronidation in Neonates: A Population Pharmacokinetic and Pharmacogenetic Study. Clinical pharmacokinetics,
  67. Linakis MW, Cook SF, Kumar SS, Liu X, Wilkins DG, Gaedigk R, Gaedigk A, Sherwin CMT, van den Anker J (2018). Polymorphic Expression of UGT1A9 is Associated with Variable Acetaminophen Glucuronidation in Neonates: A Population Pharmacokinetic and Pharmacogenetic Study. Clinical pharmacokinetics, 57(10), 1325-1336.
  68. Ward RM, Benjamin DK Jr, Davis JM, Gorman RL, Kauffman R, Kearns GL, Murphy MD, Sherwin C (2018). The Need for Pediatric Drug Development. The Journal of pediatrics, 192, 13-21.
  69. Ward RM, Benjamin DK Jr, Davis JM, Gorman RL, Kauffman R, Kearns GL, Murphy MD, Sherwin CM (2018). The Need for Pediatric Drug Development. The Journal of pediatrics, 192, 13-21.
  70. Ananthula HK, Parker S, Touchette E, Buller RM, Patel G, Kalman D, Salzer JS, Gallardo-Romero N, Olson V, Damon IK, Moir-Savitz T, Sallans L, Werner MH, Sherwin CM, Desai P (2018). Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents. BMC pharmacology & toxicology, 19(1), 80.
  71. Linakis, M.W., Rower, J.E., Roberts, J.K., Miller, E.I., Wilkins, D.G., Sherwin, C.M. (2017). Population Pharmacokinetic Model of Transdermal Nicotine Delivered from a Matrix-Type Patch. Br J Clin Pharmacol, 83(12), 2709-2717.
  72. Linakis, M.W., Rower, J.E., Roberts, J.K., Miller, E.I., Wilkins, D.G., Sherwin, C.M.T. (2017). Population pharmacokinetic model of transdermal nicotine delivered from a matrix-type patch. Br J Clin Pharmacol, 83(12), 2709-2717.
  73. Yu T, Enioutina EY, Brunner HI, Vinks AA, Sherwin C (2017). Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. Clinical pharmacokinetics, 56(2), 107-125.
  74. Rower JE, Liu X, Yu T, Mundorff M, Sherwin CM, Johnson M (2017). Clinical pharmacokinetics of magnesium sulfate in the treatment of children with severe acute asthma. European journal of clinical pharmacology, 73(3), 325-331.
  75. Tak CR, Job KM, Schoen-Gentry K, Campbell SC, Carroll P, Costantine M, Brixner D, Birnbaum AK, Sherwin CM (2017). The impact of exposure to antidepressant medications during pregnancy on neonatal outcomes: a review of retrospective database cohort studies. European journal of clinical pharmacology, 73(9), 1055-1069.
  76. Lanke S, Yu T, Rower JE, Balch AH, Korgenski EK, Sherwin C (2017). AUC-Guided Vancomycin Dosing in Adolescent Patients With Suspected Sepsis. Journal of clinical pharmacology, 57(1), 77-84.
  77. Constance JE, Reith D, Ward RM, Balch A, Stockmann C, Korgenski EK, Thorell EA, Sherwin C (2017). Risk of nonsteroidal anti-inflammatory drug-associated renal dysfunction among neonates diagnosed with patent ductus arteriosus and treated with gentamicin. Journal of perinatology, (Jun 8),
  78. Constance JE, Reith D, Ward RM, Balch A, Stockmann C, Korgenski EK, Thorell EA, Sherwin CM (2017). Risk of nonsteroidal anti-inflammatory drug-associated renal dysfunction among neonates diagnosed with patent ductus arteriosus and treated with gentamicin. Journal of perinatology, 37(10), 1093-1102.
  79. Constance JE, Campbell SC, Somani AA, Yellepeddi V, Owens KH, Sherwin C (2017). Pharmacokinetics, Pharmacodynamics and Pharmacogenetics associated with Nonsteroidal Anti-Inflammatory Drugs and Opioids in Pediatric Cancer Patients. Expert opinion on drug metabolism & toxicology, (Jun 5), 1-10.
  80. Linakis MW, Job KM, Liu X, Collingwood SC, Pangburn HA, Ott DK, Sherwin CM (2017). Riding (High) into the danger zone: a review of potential differences in chemical exposures in fighter pilots resulting from high altitude and G-forces. Expert opinion on drug metabolism & toxicology, 13(9), 925-934.
  81. Constance JE, Campbell SC, Somani AA, Yellepeddi V, Owens KH, Sherwin CM (2017). Pharmacokinetics, pharmacodynamics and pharmacogenetics associated with nonsteroidal anti-inflammatory drugs and opioids in pediatric cancer patients. Expert opinion on drug metabolism & toxicology, 13(7), 715-724.
  82. Enioutina EY, Salis ER, Job KM, Gubarev MI, Krepkova LV, Sherwin C (2017). Herbal Medicines: challenges in the modern world. Part 5. status and current directions of complementary and alternative herbal medicine worldwide. Expert review of clinical pharmacology, 10(3), 327-338.
  83. Enioutina EY, Teng L, Fateeva TV, Brown JCS, Job KM, Bortnikova VV, Krepkova LV, Gubarev MI, Sherwin CM (2017). Phytotherapy as an alternative to conventional antimicrobials: combating microbial resistance. Expert review of clinical pharmacology, 10(11), 1203-1214.
  84. Jones BL, Sherwin CM, Liu X, Dai H, Vyhlidal C (2017). Genetic Variation in the Histamine Production, Response, and Degradation Pathway Is Associated with Histamine Pharmacodynamic Response in Children with Asthma. Frontiers in pharmacology, 7, 524.
  85. Rower JE, Stockmann C, Linakis MW, Kumar SS, Liu X, Korgenski EK, Sherwin CM, Molina K (2017). Predicting Tacrolimus Concentrations in Children Receiving a Heart Transplant Using a Population Pharmacokinetic Model. BMJ paediatrics open, 1(e000147),
  86. Rower JE, Stockmann C, Linakis MW, Kumar SS, Liu X, Korgenski EK, Sherwin CMT, Molina K (2017). Predicting tacrolimus concentrations in children receiving a heart transplant using a population pharmacokinetic model. BMJ paediatrics open, 1, e000147.
  87. Rower JE,Stockmann C,Linakis MW,Kumar SS,Liu X,Kent Korgenski E,Sherwin CMT,Molina K (2017). Predicting tacrolimus concentrations in children receiving a heart transplant using a population pharmacokinetic model. BMJ paediatrics open, 1(1),
  88. Jones BL,Sherwin CMT,Liu X,Dai H,Vyhlidal C (2017). Genetic variation in the histamine production, response, and degradation pathway is associated with histamine pharmacodynamic response in children with asthma. Frontiers in pharmacology, 7(JAN),
  89. Janssen, E.J., Valitalo, P.A., Allegaert, K., de Cock.F, R...F., Simons, S.H., Sherwin, C.M., Mouton, J., van den Anker, J.N., Knibbe, C.A. (2016). Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. Antimicrob Agents Chemother, 60(2), 1031-21.
  90. Dobson, N.R., Liu, X., Rhein, L.M., Darnall, R.A., Corwin, M.J., McEntire, B.L., Ward, R.M., James, L.P., Sherwin, C.M., Heeren, T.C., Hunt, C.E. (2016). Salivary caffeine concentrations are comparable to plasma concentrations in preterm infants receiving extended caffeine therapy. Br J Clin Pharmacol, 82(3), 754-61.
  91. Cook SF, Roberts JK, Samiee-Zafarghandy S, Stockmann C, King AD, Deutsch N, Williams EF, Allegaert K, Wilkins DG, Sherwin CM, van den Anker J (2016). Population Pharmacokinetics of Intravenous Paracetamol (Acetaminophen) in Preterm and Term Neonates: Model Development and External Evaluation. Clinical pharmacokinetics, 55(1), 107-19.
  92. Linakis MW, Roberts JK, Lala AC, Spigarelli MG, Medlicott NJ, Reith DM, Ward RM, Sherwin C (2016). Challenges Associated with Route of Administration in Neonatal Drug Delivery. Clinical pharmacokinetics, 55(2), 185-96.
  93. Cook SF, Stockmann C, Samiee-Zafarghandy S, King AD, Deutsch N, Williams EF, Wilkins DG, Sherwin CM, van den Anker J (2016). Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parent-Metabolite Population Pharmacokinetic Model. Clinical pharmacokinetics, 55(11), 1395-1411.
  94. Yu T, Campbell SC, Stockmann C, Tak C, Schoen K, Clark EA, Varner MW, Spigarelli MG, Sherwin C (2016). Pregnancy-induced changes in the pharmacokinetics of caffeine and its metabolites. Journal of clinical pharmacology, 56(5), 590-6.
  95. Bhongsatiern J, Stockmann C, Yu T, Constance JE, Moorthy G, Spigarelli MG, Desai PB, Sherwin C (2016). Renal Function Descriptors in Neonates: Which Creatinine-Based Formula Best Describes Vancomycin Clearance?. Journal of clinical pharmacology, 56(5), 528-40.
  96. Liu X, Yu T, Rower JE, Campbell SC, Sherwin CM, Johnson M (2016). Optimizing the use of intravenous magnesium sulfate for acute asthma treatment in children. Pediatric pulmonology, 51(12), 1414-1421.
  97. Stockmann C, Sammons H, Starkey E, Constance JE, Sherwin C (2016). Unanswered Questions Regarding Optimal Pediatric Vancomycin Use. Therapeutic drug monitoring, 38(3), 419-20.
  98. Stockmann C, Sammons H, Starkey E, Constance JE, Sherwin C (2016). Unanswered questions regarding optimal pediatric vancomycin use. Therapeutic drug monitoring, Apr 14,
  99. Constance JE, Balch AH, Stockmann C, Linakis MW, Korgenski EK, Roberts JK, Ward RM, Sherwin CM, Spigarelli M (2016). A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates. Archives of disease in childhood. Fetal and neonatal edition, 101(3), F236-43.
  100. Liu X, Jones BL, Roberts JK, Sherwin C (2016). Population pharmacokinetic/pharmacodynamic modeling of histamine response measured by histamine iontophoresis laser Doppler. Journal of pharmacokinetics and pharmacodynamics, 43(4), 385-93.
  101. Tak C, Yu T, Sherwin CM, Mihalopoulos N (2016). Optimizing enrollment in pediatric obese patients: reflections on recruitment characteristics. International journal of adolescent medicine and health, 29(6),
  102. Tak CR, Yu T, Sherwin CMT, Mihalopoulos N (2016). Optimizing enrollment in pediatric obese patients: reflections on recruitment characteristics. International journal of adolescent medicine and health, 29(6),
  103. Job KM, Olson J, Stockmann C, Constance JE, Enioutina EY, Rower JE, Linakis MW, Balch AH, Yu T, Liu X, Thorell EA, Sherwin C (2016). Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections. Expert review of anti-infective therapy, 14(8), 731-46.
  104. Burch PT, Spigarelli MG, Lambert LM, Loftus PD, Sherwin CM, Linakis MW, Sheng X, LuAnn Minich L, Williams R (2016). Use of Oxandrolone to Promote Growth in Neonates following Surgery for Complex Congenital Heart Disease: An Open-Label Pilot Trial. Congenital heart disease, 11(6), 693-699.
  105. Barnes J, McLachlan AJ, Sherwin CM, Enioutina E (2016). Herbal medicines: challenges in the modern world. Part 1. Australia and New Zealand. Expert review of clinical pharmacology, 9(7), 905-15.
  106. Sammons HM, Gubarev MI, Krepkova LV, Bortnikova VV, Corrick F, Job KM, Sherwin CM, Enioutina E (2016). Herbal medicines: challenges in the modern world. Part 2. European Union and Russia. Expert review of clinical pharmacology, 9(8), 1117-27.
  107. Teng L, Zu Q, Li G, Yu T, Job KM, Yang X, Di L, Sherwin CM, Enioutina E (2016). Herbal medicines: challenges in the modern world. Part 3. China and Japan. Expert review of clinical pharmacology, 9(9), 1225-33.
  108. Job KM, Kiang TK, Constance JE, Sherwin CM, Enioutina E (2016). Herbal medicines: challenges in the modern world. Part 4. Canada and United States. Expert review of clinical pharmacology, 9(12), 1597-1609.
  109. Yu T, Balch AH, Ward RM, Korgenski EK, Sherwin C (2016). Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates. BMC pharmacology & toxicology, 17(1), 22.
  110. Campbell SC, Kast TT, Kamyar M, Robertson J, Sherwin C (2016). Calls to a teratogen information service regarding potential exposures in pregnancy and breastfeeding. BMC pharmacology & toxicology, 17(1), 33.
  111. Janssen, E.J., V�litalo, P.A., Allegaert, K., de Cock, R.F., Simons, S.H., Sherwin, C.M., Mouton, J.W., van den Anker, J.N., Knibbe, C.A. (2016). Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. Antimicrob Agents Chemother, 60(2), 1013-21.
  112. Stockmann, C., Spigarelli, M.G., Healy, D., Gottschlich, M., Kagan, R., Balch, A.H., Sherwin, C.M. (2015). Application of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data. Biopharm Drug Dispos, 12(Epub).
  113. Stockmann, C., Spigarelli, M.G., Healy, D.P., Gottschlich, M.M., Kagan, R., Balch, A.H., Sherwin, C. (2015). Application of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data. Biopharm Drug Dispos, 36(6), 405-409.
  114. Lala, A.C., Broadbent, R.S., Medlicott, N.J., Sherwin, C.M., Reith, D.M. (2015). Illustrative neonatal cases regarding drug delivery issues. J Paediatr Child Health, 51(5), 478-481.
  115. Stockmann C, Roberts JK, Yellepeddi VK, Sherwin C (2015). Clinical pharmacokinetics of inhaled antimicrobials. Clinical pharmacokinetics, 54(5), 473-92.
  116. Roberts JK, Stockmann C, Ward RM, Beachy J, Baserga MC, Spigarelli MG, Sherwin C (2015). Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy. Clinical pharmacokinetics, 54(12), 1237-44.
  117. Balch AH, Constance JE, Thorell EA, Stockmann C, Korgenski EK, Campbell SC, Spigarelli MG, Sherwin C (2015). Pediatric vancomycin dosing: Trends over time and the impact of therapeutic drug monitoring. Journal of clinical pharmacology, 55(2), 212-20.
  118. Linakis MW, Stockmann C, Campbell SC, Williams RV, Burch PT, Lambert LM, Sherwin CM, Reilly CA, Spigarelli M (2015). Quantitative Assay Validation for Oxandrolone in Human Plasma Using LC-MS-MS. Journal of analytical toxicology, 39(7), 526-31.
  119. Baserga MC, Beachy JC, Roberts JK, Ward RM, DiGeronimo RJ, Walsh WF, Ohls RK, Anderson J, Mayock DE, Juul SE, Christensen RD, Loertscher MC, Stockmann C, Sherwin CM, Spigarelli MG, Yoder B (2015). Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. Pediatric research, 78(3), 315-22.
  120. Baserga MC, Beachy JC, Roberts JK, Ward RM, DiGeronimo RJ, Walsh WF, Ohls RK, Anderson J, Mayock DE, Juul SE, Christensen RD, Loertscher MC, Stockmann C, Sherwin CM, Spigarelli MG, Yoder B (2015). Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. Pediatric research, 78(3), 315-22.
  121. Stockmann C, Ampofo K, Pavia AT, Byington CL, Blaschke AJ, Sherwin CM, Spigarelli MG, Hersh A (2015). National trends in the incidence, outcomes and charges of pediatric osteoarticular infections, 1997-2012. The Pediatric infectious disease journal, 34(6), 672-4.
  122. Bhongsatiern J, Stockmann C, Roberts JK, Yu T, Korgenski KE, Spigarelli MG, Desai PB, Sherwin C (2015). Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ¿400 Target. Therapeutic drug monitoring, 37(6), 756-65.
  123. Constance JE, Balch AH, Stockmann C, Linakis MW, Korgenski EK, Roberts JK, Ward RM, Sherwin CM, Spigarelli M (2015). A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates. Archives of disease in childhood. Fetal and neonatal edition, Sep 23,
  124. Sherwin CM, Stockmann C, Grimsrud K, Herd DW, Anderson BJ, Spigarelli M (2015). Development of an optimal sampling schedule for children receiving ketamine for short-term procedural sedation and analgesia. Paediatric anaesthesia, 25(2), 211-6.
  125. Roberts JK, Stockmann C, Balch A, Yu T, Ward RM, Spigarelli MG, Sherwin C (2015). Optimal design in pediatric pharmacokinetic and pharmacodynamic clinical studies. Paediatric anaesthesia, 25(3), 222-30.
  126. Ward RM, Sherwin C (2015). Ethics of drug studies in the newborn. Paediatric drugs, 17(1), 37-42.
  127. Yu T, Stockmann C, Healy DP, Olson J, Wead S, Neely AN, Kagan RJ, Spigarelli MG, Sherwin C (2015). Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis. Journal of burn care & research, 36(4), e244-52.
  128. Stockmann C, Gottschlich MM, Healy D, Khoury JC, Mayes T, Sherwin CM, Spigarelli MG, Kagan R (2015). Relationship between zolpidem concentrations and sleep parameters in pediatric burn patients. Journal of burn care & research, 36(1), 137-44.
  129. Stockmann C, Roberts JK, Knackstedt ED, Spigarelli MG, Sherwin C (2015). Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection. Expert opinion on drug metabolism & toxicology, 11(2), 205-19.
  130. Enioutina EY, Constance JE, Stockmann C, Linakis MW, Yu T, Rower JE, Balch AH, Sherwin C (2015). Pharmacokinetic considerations in the use of antivirals in neonates. Expert opinion on drug metabolism & toxicology, 11(12), 1861-78.
  131. Roberts JK, Cook SF, Stockmann C, Rollins DE, Wilkins DG, Sherwin C (2015). A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults. Clinical drug investigation, 35(10), 633-43.
  132. Stockmann C, Hillyard B, Ampofo K, Spigarelli MG, Sherwin C (2015). Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis. Expert review of respiratory medicine, 9(1), 13-22.
  133. Yang X, Sherwin CM, Yu T, Yellepeddi VK, Brunner HI, Vinks A (2015). Pharmacokinetic modeling of therapies for systemic lupus erythematosus. Expert review of clinical pharmacology, 8(5), 587-603.
  134. Grimsrud KN, Sherwin CM, Constance JE, Tak C, Zuppa AF, Spigarelli MG, Mihalopoulos N (2015). Special population considerations and regulatory affairs for clinical research. Clinical research and regulatory affairs, 32(2), 47-56.
  135. Stockmann C, Barrett JS, Roberts JK, Sherwin C (2015). Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens. CPT, 4(11), 630-40.
  136. Stockmann C, Barrett JS, Roberts JK, Sherwin (2015). Use of Modeling and Simulation in the Design and Conduct of Pediatric Clinical Trials and the Optimization of Individualized Dosing Regimens. CPT, 4(11), 630-40.
  137. Stockmann C, Hersh AL, Roberts JK, Bhongsatiern J, Korgenski EK, Spigarelli MG, Sherwin CM, Frymoyer (2015). Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates. Infectious diseases and therapy, 4(2), 187-98.
  138. Stockmann C,Barrett JS,Roberts JK,Sherwin CM (2015). Use of modeling and simulation in the design and conduct of pediatric clinical trials and the optimization of individualized dosing regimens. CPT, 4(11), 630-640.
  139. Stockmann C,Spigarelli MG,Healy DP,Gottschlich MM,Kagan R,Balch AH,Sherwin (2015). Application of a method used to deconstruct a single dose pharmacokinetic profile from multiple dose data. Biopharmaceutics & drug disposition, 36(6), 405-409.
  140. Stockmann C,Hersh AL,Roberts JK,Bhongsatiern J,Korgenski EK,Spigarelli MG,Sherwin CMT,Frymoyer (2015). Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates. Infectious diseases and therapy, 4(2), 187-198.
  141. Sherwin, C.M., Medlicott, N.J., Reith, D.M., Broadbent, R.S. (2014). Intravenous drug delivery in neonates: lessons learnt. Arch Dis Child, 99(6), 590-4.
  142. Sherwin, C.M., Wead, S., Stockmann, C., Healy, D., Spigarelli, M.G., Neely, A., Kagan, R. (2014). Amikacin population pharmacokinetics among paediatric burn patients. Burns, 40(2), 311-8.
  143. Lala, A.C., Broadbent, R.S., Medlicott, N.J., Sherwin, C.M., Reith, D.M. (2014). Illustrative neonatal cases regarding drug delivery issues. J Paediatr Child Health.
  144. Stockmann C, Constance JE, Roberts JK, Olson J, Doby EH, Ampofo K, Stiers J, Spigarelli MG, Sherwin C (2014). Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. Clinical pharmacokinetics, 53(5), 429-54.
  145. Roberts JK, Stockmann C, Constance JE, Stiers J, Spigarelli MG, Ward RM, Sherwin C (2014). Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants. Clinical pharmacokinetics, 53(7), 581-610.
  146. Stockmann C, Hersh AL, Sherwin CM, Spigarelli M (2014). Alignment of United States funding for cardiovascular disease research with deaths, years of life lost, and hospitalizations. International journal of cardiology, 172(1), e19-21.
  147. Stockmann C, Sherwin CM, Koren G, Campbell SC, Constance JE, Linakis M, Balch A, Varner MW, Spigarelli M (2014). Characteristics and publication patterns of obstetric studies registered in ClinicalTrials.gov. Journal of clinical pharmacology, 54(4), 432-7.
  148. Lacher SE, Gremaud JN, Skagen K, Steed E, Dalton R, Sugden KD, Cardozo-Pelaez F, Sherwin CM, Woodahl E (2014). Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat. The Journal of pharmacology and experimental therapeutics, 348(2), 336-45.
  149. De Cock RF, Allegaert K, Sherwin CM, Nielsen EI, de Hoog M, van den Anker JN, Danhof M, Knibbe C (2014). A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharmaceutical research, 31(3), 754-67.
  150. De Cock RF, Allegaert K, Brussee JM, Sherwin CM, Mulla H, de Hoog M, van den Anker JN, Danhof M, Knibbe C (2014). Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharmaceutical research, 31(10), 2643-54.
  151. Stockmann C, Sherwin CM, Buterbaugh W, Spigarelli MG, Gottschlich MM, Healy D, Kagan R (2014). Preliminary assessment of zolpidem pharmacokinetics in pediatric burn patients. Therapeutic drug monitoring, 36(3), 295-301.
  152. Campbell SC, Stockmann C, Balch A, Clark EA, Kamyar M, Varner M, Korgenski EK, Bonkowsky JL, Spigarelli MG, Sherwin C (2014). Intrapartum magnesium sulfate and the potential for cardiopulmonary drug-drug interactions. Therapeutic drug monitoring, 36(4), 544-8.
  153. Yu T, Stockmann C, Balch AH, Spigarelli MG, Sherwin C (2014). Evolution of interventional vancomycin trials in light of new antibiotic development in the USA, 1999-2012. International journal of antimicrobial agents, 43(3), 215-22.
  154. Stockmann C, Spigarelli MG, Campbell SC, Constance JE, Courter JD, Thorell EA, Olson J, Sherwin C (2014). Considerations in the pharmacologic treatment and prevention of neonatal sepsis. Paediatric drugs, 16(1), 67-81.
  155. Schoen K, Yu T, Stockmann C, Spigarelli MG, Sherwin C (2014). Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity. Paediatric drugs, 16(2), 169-77.
  156. Sherwin CM, Zobell JT, Stockmann C, McCrory BE, Wisdom M, Young DC, Olson J, Ampofo K, Spigarelli M (2014). Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis. Journal of pharmacokinetics and pharmacodynamics, 41(1), 71-9.
  157. Sherwin CM, Balch A, Campbell SC, Fredrickson J, Clark EA, Varner M, Stockmann C, Korgenski EK, Bonkowsky JL, Spigarelli M (2014). Maternal magnesium sulphate exposure predicts neonatal magnesium blood concentrations. Basic & clinical pharmacology & toxicology, 114(4), 318-22.
  158. Stockmann C, Roberts JK, Yu T, Constance JE, Knibbe CA, Spigarelli MG, Sherwin C (2014). Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. Expert review of anti-infective therapy, 12(11), 1371-1388.
  159. Stockmann C, Roberts JK, Yu T, Constance JE, Knibbe CA, Spigarelli MG, Sherwin C (2014). Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. Expert review of anti-infective therapy, 12(11), 1371-88.
  160. Yakub SY, Constance JE, Stockmann C, Linakis M, Campbell SC, Sherwin CM, Korgenski EK, Balch A, Spigarelli M (2014). Epidemiological Evaluation of Blood Culture among Neonates Receiving Vancomycin. Indian journal of microbiology, 54(4), 389-395.
  161. Yakub SY, Constance JE, Stockmann C, Linakis M, Campbell SC, Sherwin CM, Korgenski EK, Balch A, Spigarelli M (2014). Epidemiological Evaluation of Blood Culture Patterns among Neonates Receiving Vancomycin. Indian journal of microbiology, 54(4), 389-95.
  162. Sherwin CM, Ngamprasertwong P, Sadhasivam S, Vinks A (2014). Utilization of optimal study design for maternal and fetal sheep propofol pharmacokinetics study: a preliminary study. Current clinical pharmacology, 9(1), 64-9.
  163. Stockmann C, Sherwin CM, Ampofo K, Spigarelli M (2014). Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis. Therapeutic advances in respiratory disease, 8(1), 13-21.
  164. Doll E, Wilkes J, Cook LJ, Korgenski EK, Faix RG, Yoder BA, Srivastava R, Sherwin CM, Spigarelli MG, Clark EA, Bonkowsky J (2014). Neonatal magnesium levels correlate with motor outcomes in premature infants: a long-term retrospective cohort study. Frontiers in pediatrics, 2, 120.
  165. Doll E,Wilkes J,Cook LJ,Korgenski EK,Faix RG,Yoder BA,Srivastava R,Sherwin CMT,Spigarelli MG,Clark EAS,Bonkowsky J (2014). Neonatal magnesium levels correlate with motor outcomes in premature infants: A long-term retrospective cohort study. Frontiers in pediatrics, 2(NOV),
  166. Yakub SY,Constance JE,Stockmann C,Linakis M,Campbell SC,Sherwin CMT,Korgenski EK,Balch A,Spigarelli M (2014). Epidemiological Evaluation of Blood Culture Patterns among Neonates Receiving Vancomycin. Indian journal of microbiology, 54(4), 389-395.
  167. Lacher S,Gremaud J,Skagen K,Steed E,Dalton R,Sugden K,Cardozo-Pelaez F,Sherwin C,Woodahl (2014). Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquats. The Journal of pharmacology and experimental therapeutics, 348(2), 336-345.
  168. Sherwin, C.M., Nasr, M.A., Gale, E., Petek, M., Stafford, K., Turp, M., Coles, G.C. (2013). Prevalence of nematode infection and faecal egg counts in free-range laying hens: relations to housing and husbandry. Br Poult Sci, 54(1), 12-23.
  169. Jones BL, Kearns G, Neville KA, Sherwin CM, Spigarelli MM, Leeder J (2013). Variability of histamine pharmacodynamic response in children with allergic rhinitis. Journal of clinical pharmacology, 53(7), 731-7.
  170. Young DC, Zobell JT, Stockmann C, Waters CD, Ampofo K, Sherwin CM, Spigarelli M (2013). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. Pediatric pulmonology, 48(11), 1047-61.
  171. Zobell JT, Young DC, Waters CD, Ampofo K, Stockmann C, Sherwin CM, Spigarelli MG (2013). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary. Pediatric pulmonology, 48(6), 525-37.
  172. Stockmann C, Sherwin CM, Zobell JT, Young DC, Waters CD, Spigarelli MG, Ampofo K (2013). Optimization of Anti-pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: III. Fluoroquinolones. Pediatric pulmonology, 48(3), 211-20.
  173. Zobell JT, Young DC, Waters D, Stockmann C, Ampofo K, Sherwin CM, Spigarelli MG (2013). Optimization of Anti-pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: II. Cephalosporins and Penicillins. Pediatric pulmonology, 48(2), 107-22.
  174. Young DC, Zobell JT, Waters CD, Ampofo K, Stockmann C, Sherwin CM, Spigarelli MG (2013). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. Colistimethate sodium. Pediatric pulmonology, 48(1), 1-7.
  175. Zobell JT, Young DC, Waters CD, Ampofo K, Stockmann C, Sherwin CM, Spigarelli M (2013). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary. Pediatric pulmonology, 48(6), 525-37.
  176. Stockmann C, Sherwin CM, Zobell JT, Young DC, Waters CD, Spigarelli MG, Ampofo (2013). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. Pediatric pulmonology, 48(3), 211-20.
  177. Zobell JT, Waters CD, Young DC, Stockmann C, Ampofo K, Sherwin CM, Spigarelli M (2013). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins. Pediatric pulmonology, 48(2), 107-22.
  178. Young DC, Zobell JT, Waters CD, Ampofo K, Stockmann C, Sherwin CM, Spigarelli M (2013). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium. Pediatric pulmonology, 48(1), 1-7.
  179. Stockmann C, Sherwin CM, Zobell JT, Lubsch L, Young DC, Olson J, Noyes BE, Ampofo K, Spigarelli M (2013). Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis. Pharmacotherapy, 33(12), 1288-96.
  180. Lambton SL, Nicol CJ, Friel M, Main DC, McKinstry JL, Sherwin CM, Walton J, Weeks C (2013). A bespoke management package can reduce levels of injurious pecking in loose-housed laying hen flocks. The Veterinary record, 172(16), 423.
  181. Stockmann C, Sherwin CM, Ampofo K, Hersh AL, Pavia AT, Byington CL, Ward RM, Spigarelli M (2013). Characteristics of antimicrobial studies registered in the USA through ClinicalTrials.Gov. International journal of antimicrobial agents, 42(2), 161-6.
  182. Stockmann C, Spigarelli MG, Ampofo K, Sherwin C (2013). Bioequivalence and Bioavailability Clinical Trials: A Status Report from the National Institutes of Health ClinicalTrials.gov Registry. Journal of bioequivalence & bioavailability, 5, 244-247.
  183. Stockmann C,Spigarelli MG,Ampofo K,Sherwin CM (2013). Bioequivalence and bioavailability clinical trials: A status report from the national institutes of health ClinicalTrials.gov registry. Journal of bioequivalence & bioavailability, 5(6), 244-247.
  184. Sherwin, C.M., Sagcal-Gironella, A.C., Fukuda, T., Brunner, H.I., Vinks, A.A. (2012). Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. Br J Clin Pharmacol, 73(5), 727-40.
  185. De Cock RF, Allegaert K, Schreuder MF, Sherwin CM, de Hoog M, van den Anker JN, Danhof M, Knibbe C (2012). Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clinical pharmacokinetics, 51(2), 105-17.
  186. Sherwin CM, Kiang TK, Spigarelli MG, Ensom M (2012). Fundamentals of population pharmacokinetic modelling: validation methods. Clinical pharmacokinetics, 51(9), 573-90.
  187. Kiang TK, Sherwin CM, Spigarelli MG, Ensom M (2012). Fundamentals of Population Pharmacokinetic Modelling : Modelling and Software. Clinical pharmacokinetics, 51(8), 515-525.
  188. Zobell JT, Waters D, Young DC, Stockmann C, Ampofo K, Sherwin CM, Spigarelli MG (2012). Optimization of Anti-pseudomonal Antibiotics for Cystic Fibrosis Pulmonary Exacerbations: I. Aztreonam and Carbapenems. Pediatric pulmonology, 47(12), 1147-58.
  189. Zobell JT, Young DC, Waters CD, Stockmann C, Ampofo K, Sherwin CM, Spigarelli M (2012). Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. Pediatric pulmonology, 47(12), 1147-58.
  190. Sherwin CM, Saldaña SN, Bies RR, Aman MG, Vinks A (2012). Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. Therapeutic drug monitoring, 34(5), 535-44.
  191. Sagcal-Gironella, A.C., Sherwin, C.M., Tirona, R.G., Rieder, M.J., Brunner, H.I., Vinks, A.A. (2011). Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study. Clin Ther, 33(10), 1524-36.
  192. Zobell, J.T., Stockmann, C., Young, D.C., Cash, J., McDowell, B.J., Korgenski, K., Sherwin, C.M., Spigarelli, M., Chatfield, B.A., Ampofo, K. (2011). Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients. Clin Ther, 33(11), 1844-50.
  193. Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks A (2011). The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clinical pharmacokinetics, 50(1), 1-24.
  194. Merhar SL, Schibler KR, Sherwin CM, Meinzen-Derr J, Shi J, Balmakund T, Vinks A (2011). Pharmacokinetics of levetiracetam in neonates with seizures. The Journal of pediatrics, 159(1), 152-154.e3.
  195. Sagcal-Gironella AC, Fukuda T, Wiers K, Cox S, Nelson S, Dina B, Sherwin CM, Klein-Gitelman MS, Vinks AA, Brunner H (2011). Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Seminars in arthritis and rheumatism, 40, 307-313.
  196. Sagcal-Gironella AC, Fukuda T, Wiers K, Cox S, Nelson S, Dina B, Sherwin CM, Klein-Gitelman MS, Vinks AA, Brunner H (2011). Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Seminars in arthritis and rheumatism, 40(4), 307-13.
  197. Sherwin CM, Ding L, Kaplan J, Spigarelli MG, Vinks A (2011). Optimal study design for pioglitazone in septic pediatric patients. Journal of pharmacokinetics and pharmacodynamics, 38, 433-447.
  198. Sherwin CM, Ding L, Kaplan J, Spigarelli MG, Vinks A (2011). Optimal study design for pioglitazone in septic pediatric patients. Journal of pharmacokinetics and pharmacodynamics, 38(4), 433-47.
  199. Merhar S,Schibler K,Sherwin C,Meinzen-Derr J,Shi J,Balmakund T,Vinks (2011). Pharmacokinetics of levetiracetam in neonates with seizures. The Journal of pediatrics, 159(1),
  200. Sherwin, C.M., Kostan, E., Broadbent, R.S., Medlicott, N.J., Reith, D.M. (2009). Evaluation of the effect of intravenous volume expanders upon the volume of distribution of gentamicin in septic neonates. Biopharm Drug Dispos, 30(5), 276-80.
  201. Sherwin CM, Svahn S, van der Linden AJ, Medlicott NJ, Broadbent R, Reith D (2009). Individualised Dosing of Amikacin in Neonates: a Pharmacokinetic/ Pharmacodynamic Analysis. European journal of clinical pharmacology, 65(7), 705-13.
  202. Sherwin CM, Svahn S, Van der Linden A, Broadbent RS, Medlicott NJ, Reith D (2009). Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. European journal of clinical pharmacology, 65(7), 705-13.
  203. Sherwin CM, McCaffrey F, Broadbent RS, Reith DM, Medlicott N (2009). Discrepancies between predicted and observed rates of intravenous gentamicin delivery for neonates. The Journal of pharmacy and pharmacology, 61(4), 465-71.
  204. Sherwin, C., Broadbent, R., Young, S., Worth, J., McCaffrey, F., Medlicott, N.J., Reith, D. (2008). Utility of interleukin-12 and interleukin-10 in comparison with other cytokines and acute-phase reactants in the diagnosis of neonatal sepsis. Am J Perinatol, 25(10), 629-36.
  205. Sherwin CM, Broadbent RS, Medlicott NJ, Reith D (2008). Individualising netilmicin dosing in neonates. European journal of clinical pharmacology, 64(12), 1201-8.
  206. Sherwin CM, Medlicott NJ, Broadbent RS and Reith D (2008). Neonatal sepsis and aminoglycosides. April(4), 16-21.
  207. Mishra S, Storer MK, Sherwin CM, Lewis J (2005). A simple binding assay for the direct determination of biotin in urine. Clinica chimica acta; international journal of clinical chemistry, 360(1-2), 60-6.

Review

  1. Farsani HA,Heidari-Soureshjani S,Sherwin CMT,Tafrishi-Nejad A,Azadegan-Dehkordi (2024). The Analgesic Effect of Ginger on Postoperative Pain: A Systematic Review of Clinical Trials. The natural products journal, 14(2),
  2. Khosravi MR,Raeisi E,Heidari-Soureshjani S,Sherwin CM (2024). The survey of antitumor effects of bromelain on neoplastic breast cells: A systematic review. Journal of HerbMed Pharmacology, 13(1), 10-18.
  3. Forootan M,Amiri MM,Darvishi M,Sherwin CMT,Ghanadi (2024). The Therapeutic Effects of Bromelain against Colorectal Cancer: A Systematic Review. Current cancer therapy reviews, 20(4), 402-409.
  4. Shabanian Boroujeni Z,Heidari-Soureshjani S,Sherwin CM (2024). Effects of Curcuma longa (turmeric) and curcumin on the premenstrual syndrome and dysmenorrhea: A systematic review. Journal of endometriosis and pelvic pain disorders, 16(1), 33-44.
  5. Sayre CL,Yellepeddi VK,Job KM,Krepkova LV,Sherwin CMT,Enioutina E (2023). Current use of complementary and conventional medicine for treatment of pediatric patients with gastrointestinal disorders. Frontiers in pharmacology, 14,
  6. Kasiri K,Sherwin CMT,Rostamian S,Heidari-Soureshjani (2023). Assessment of the Relationship Between Gastric-Acid Suppressants and the Risk of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis. Current therapeutic research, clinical and experimental, 98,
  7. Sayre CL, Yellepeddi VK, Job KM, Krepkova LV, Sherwin CMT, Enioutina E (2023). Current use of complementary and conventional medicine for treatment of pediatric patients with gastrointestinal disorders. Frontiers in pharmacology, 14, 1051442.
  8. Kasiri K, Sherwin CMT, Rostamian S, Heidari-Soureshjani (2023). Assessment of the Relationship Between Gastric-Acid Suppressants and the Risk of Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis. Current therapeutic research, clinical and experimental, 98, 100692.
  9. Hudson RE, Metz TD, Ward RM, McKnite AM, Enioutina EY, Sherwin CM, Watt KM, Job K (2023). Drug exposure during pregnancy: Current understanding and approaches to measure maternal-fetal drug exposure. Frontiers in pharmacology, 14, 1111601.
  10. Ghahfarrokhi SH,Heidari-Soureshjani S,Talebi-Boroujeni P,Sherwin CM (2023). Effect and Mechanism of Curcumin on Bone Loss and Osteoporosis: A Systematic Review. Current Traditional Medicine, 9(6), 145-154.
  11. Emami E,Talebi-Boroujeni P,Sherwin CMT,Heidari-Soureshjani S,Mohammadi (2023). Effect of Curcumin on Oxidative Stress, Inflammatory Response and Kidney Biochemical Parameters Among Kidney Disease Patients: A Systematic Review. The natural products journal, 13(5), 86-97.
  12. Hudson RE,Metz TD,Ward RM,McKnite AM,Enioutina EY,Sherwin CM,Watt KM,Job K (2023). Drug exposure during pregnancy: Current understanding and approaches to measure maternal-fetal drug exposure. Frontiers in pharmacology, 14,
  13. Juberg DR, Fox DA, Forcelli PA, Kacew S, Lipscomb JC, Saghir SA, Sherwin CM, Koenig CM, Hays SM, Kirman C (2023). A perspective on In vitro developmental neurotoxicity test assay results: An expert panel review. Regulatory toxicology and pharmacology, 143, 105444.
  14. Habibi Ghahfarrokhi S, Mohammadian-Hafshejani A, Sherwin CMT, Heidari-Soureshjani (2022). Relationship between serum vitamin D and hip fracture in the elderly: a systematic review and meta-analysis. Journal of bone and mineral metabolism, 40(4), 541-553.
  15. Hudson RE, Job KM, Sayre CL, Krepkova LV, Sherwin CM, Enioutina E (2022). Examination of Complementary Medicine for Treating Urinary Tract Infections Among Pregnant Women and Children. Frontiers in pharmacology, 13, 883216.
  16. Sherwin CMT,Heidari-Soureshjani (2022). Effects and Mechanisms of Medicinal Plants on Healing Scars: A Systematic Review. Current Traditional Medicine, 8(1),
  17. Hudson RE,Job KM,Sayre CL,Krepkova LV,Sherwin CM,Enioutina E (2022). Examination of Complementary Medicine for Treating Urinary Tract Infections Among Pregnant Women and Children. Frontiers in pharmacology, 13,
  18. Farahbod F,Talebi-Boroujeni P,Sherwin CMT,Heidari-Soureshjani (2022). Effectiveness of phosphodiesterase type 5 inhibitors on the treatment of thin endometrium and pregnancy outcomes: An systematic review. Journal of endometriosis and pelvic pain disorders, 14(3), 132-142.
  19. Avachat C,Barry JM,Lyu X,Sherwin CM,Birnbaum A (2022). Management of Anti-Seizure Medications during Pregnancy: Advancements in The Past Decade. Pharmaceutics, 14(12),
  20. Avachat C, Barry JM, Lyu X, Sherwin CM, Birnbaum A (2022). Management of Anti-Seizure Medications during Pregnancy: Advancements in The Past Decade. Pharmaceutics, 14(12),
  21. Krepkova LV, Babenko AN, Saybel' OL, Lupanova IA, Kuzina OS, Job KM, Sherwin CM, Enioutina E (2021). Valuable Hepatoprotective Plants - How Can We Optimize Waste Free Uses of Such Highly Versatile Resources?. Frontiers in pharmacology, 12, 738504.
  22. Job KM, Roberts JK, Enioutina EY, Illamola SM, Kumar SS, Rashid J, Ward RM, Fukuda T, Sherbotie J, Sherwin C (2021). Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients. Expert opinion on drug metabolism & toxicology, 17(7), 747-765.
  23. Kingma JS, Burgers DMT, Monpellier VM, Wiezer MJ, Blussé van Oud-Alblas HJ, Vaughns JD, Sherwin CMT, Knibbe CA (2021). Oral drug dosing following bariatric surgery: General concepts and specific dosing advice. British journal of clinical pharmacology, 87(12), 4560-4576.
  24. Krepkova LV,Babenko AN,Saybel¿ OL,Lupanova IA,Kuzina OS,Job KM,Sherwin CM,Enioutina E (2021). Valuable Hepatoprotective Plants - How Can We Optimize Waste Free Uses of Such Highly Versatile Resources?. Frontiers in pharmacology, 12,
  25. Enioutina EY, Job KM, Krepkova LV, Reed MD, Sherwin C (2020). How can we improve the safe use of herbal medicine and other natural products? A clinical pharmacologist mission. Expert review of clinical pharmacology, 13(9), 935-944.
  26. Mohammadian-Hafshejani A, Sherwin CMT, Heidari-Soureshjani (2020). Do statins play any role in reducing the incidence and mortality of ovarian cancer? A systematic review and meta-analysis. Journal of preventive medicine and hygiene, 61(3), E331-E339.
  27. Thyagarajan A,Alshehri M,Miller K,Sherwin C,Travers J,Sahu (2019). Myeloid-derived suppressor cells and pancreatic cancer: Implications in novel therapeutic approaches. Cancers, 11(11),
  28. Yellepeddi V, Rower J, Liu X, Kumar S, Rashid J, Sherwin C (2018). State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development. Clinical pharmacokinetics,
  29. Tak CR, Job KM, Schoen-Gentry K, Campbell SC, Carroll P, Costantine M, Brixner D, Birnbaum AK, Sherwin C (2017). The impact of exposure to antidepressant medications during pregnancy on neonatal outcomes: a review of retrospective database cohort studies. European journal of clinical pharmacology, (Jun 9),
  30. Linakis MW, Job KM, Liu X, Collingwood SC, Pangburn HA, Ott DK, Sherwin C (2017). Riding (High) into the Danger Zone: A Review of Potential Differences in Chemical Exposures in Fighter Pilots Resulting from High Altitude and G-forces. Expert opinion on drug metabolism & toxicology, 13(9), 925-934.
  31. Enioutina EY, Brown J, Fateeva TV, Teng L, Job KM, Bortnikova VV, Krepkova LV, Gubarev MI, Sherwin C (2017). Phytotherapy as an alternative to conventional antimicrobials: Combating microbial resistance. Expert review of clinical pharmacology, 10(11), 1203-1214.
  32. Kaur I, Constance JE, Kosak KM, Spigarelli MG, Sherwin C (2015). An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia. Expert opinion on drug metabolism & toxicology, 11(1), 53-65.
  33. Grimsrud KN,Sherwin CMT,Constance JE,Tak C,Zuppa AF,Spigarelli MG,Mihalopoulos N (2015). Special population considerations and regulatory affairs for clinical research. Clinical research and regulatory affairs, 32(2), 47-56.
  34. Lala AC,Broadbent RS,Medlicott NJ,Sherwin CMT,Reith D (2015). Illustrative neonatal cases regarding drug delivery issues. Journal of paediatrics and child health, 51(5), 478-481.
  35. Campbell SC, Spigarelli MG, Courter J, Sherwin C (2013). Metabolic and toxicological considerations for sepsis drug treatments. Expert opinion on drug metabolism & toxicology, 9(1), 79-89.
  36. Kiang TK, Sherwin CM, Spigarelli MG, Ensom M (2012). Fundamentals of population pharmacokinetic modelling: modelling and software. Clinical pharmacokinetics, 51(8), 515-25.

Edited Book

  1. Ene E, Bunbridge R, Bies R, Sherwin C Pharmacometrics: The Science of Quantitative Pharmacology.

Book Chapter

  1. Yellepeddi VK,Roberts JK,Escobar L,Sayre C,Sherwin C (2018). The Relationship Between Pharmacogenomics and Pharmacokinetics and Its Impact on Drug Choice and Dosing Regimens in Pediatrics. ADME Processes in Pharmaceutical Sciences: Dosage, Design, and Pharmacotherapy Success, 203-222.
  2. de Cock, PAJG, Allegaert, K, Linakis, MW, Sherwin C (2017). Antibiotic dosing in paediatric critically ill patients. 239-263.
  3. De Cock PAJG,Allegaert K,Linakis MW,Sherwin CM (2017). Antibiotic dosing in pediatric critically Ill patients. Antibiotic Pharmacokinetic/Pharmacodynamic Considerations in the Critically Ill, 239-263.
  4. Krekels EHJ,Rower JE,Constance JE,Knibbe CAJ,Sherwin CM (2017). Hepatic Drug Metabolism in Pediatric Patients. Drug Metabolism in Diseases, 181-206.
  5. Campbell SC, Salisbury LM, Roberts JK, Kamyar M, Fredrickson J, Costantine MM, Sherwin C (2016). Therapeutic Drug Monitoring in Pregnancy. 185-211.
  6. Krekels EHJ, Rower JE, Constance JE, Knibbe CAJ, Sherwin C (2016). Hepatic Drug Metabolism in Pediatric Patients. 181¿206.
  7. Campbell S,Salisbury L,Roberts J,Kamyar M,Fredrickson J,Costantine M,Sherwin (2016). Therapeutic Drug Monitoring in Pregnancy. Clinical Challenges in Therapeutic Drug Monitoring: Special Populations, Physiological Conditions, and Pharmacogenomics, 185-211.
  8. Stockmann C, Roberts JK, Savic RM, Sherwin C Design and analysis of Pediatric Clinical Trials.
  9. Kumar SS, Duong JK, Liu X, Sherwin C Clinical Trial Simulation.

Conference Proceedings

  1. Biltaji E, Korgenski EK, Sherwin CM, Constance J (2018). Predictors of liver toxicity associated with voriconazole exposure among pediatric and young adult patients. 103, S25-S25.
  2. Liu X, Wang Y, Sherwin C (2018). Evaluating the performance of classical pk models, 2nd-gen MPBPK models and MPBPK models with TMDD in predicting therapeutic monoclonal antibody PK in human. 103, S78-S78.
  3. Ivanova X, Liu X, Tran V, Sullivan K, Wead S, Neely A, Kagan R, Healy D, Sherwin C (2018). Influence of Demographic and Clinical Variables on Vancomycin Trough Values in Pediatric Burn Patients. 39(suppl 1), S73-S73.
  4. Plumage E, Illamola S, Balch A, Sherwin C (2018). Therapeutic Drug Monitoring in Pediatric Heart Transplant Patients Receiving Mycophenolate Mofetil. 103, S47-S47.
  5. Grimsrud KN, Ivanova X, Sherwin CM, Palmieri T, Tran N (2018). Identification of Cytochrome P450 Polymorphisms in Burn Patients and Impact on Fentanyl Pharmacokinetics. 39(suppl 1), S34-S34.
  6. Balch, A.H., Kumar, S.S., Rower, J., Illamola, S.M., Liu, X., Korgenski, K., Yoo, J., Kim, H., Wang, J., Zhang, X., Sherwin, C.M. (2018). Statistical Properties of the pAUC metric in Pediatric Kidney Patients receiving Tacrolimus. American Society for Clinical Pharmacology and Therapeutics, ASCPT 2018, Orlando FL.
  7. May L, Liu X, Sherwin CM, Yang L, Zehnder J, Lee J, Lo C, Chen S, Rosenthal DN, McElhinney DB, Almond C (2017). Use of TEG/Platelet Mapping to Dose-Adjust Platelet Inhibitors in Children Supported with the Berlin EXCOR: In Search of a Correlation. 36(4), S278-S279.
  8. Wang Y, Liu X, Olson J, Korgenski EK, Thorell EA, Sherwin C (2017). Population pharmacokinetic modeling and dosing regimen optimization of intravenous gentamicin in pediatric population. 101(S1),
  9. Liu X, Jones BL, Roberts JK, Sherwin C (2017). Population pharmacokinetic/pharmacodynamics modeling of histamine response measured by histamine iontophoresis laser Doppler. 101(S1),
  10. Job KM, Sanders C, Hillyard B, Rower JE, Korgenski EK, Sherwin C (2017). Trends of Calcineurin Inhibitor Use in Pediatric Immunosuppression. 101(S1),
  11. Ivanova X, Liu X, Tran N, Wead S, Kagan RJ, Healy DP, Sherwin C (2017). Pharmacokinetic Model for Vancomycin in Pediatric Burn Patients. 101(S1),
  12. Kumar SS, Liu X, Sherwin CM, Jones B (2017). Determining the Reliability of Histamine response phenotype classification: a population modelling approach. 101(S1),
  13. Balch AH, Constance J, Kumar SS, Korgenski EK, Sherbotie JR, Yu T, Sherwin C (2017). Do physicians change tacrolimus dosing after 90 days? An EMR-based study of therapeutic drug monitoring in transplant patients. 101(S1), S56.
  14. Linakis MW, Liu X, Cook SF, Kumar SS, Wilkins DG, Gaedigk R, Gaedigk A, Sherwin CM, van den Anker J (2017). UGT1A9 RS3832043 influences acetaminophen glucuronidation in neonates. 101(S1), S8.
  15. Liu X, Smits A, Wang Y, Wead S, Kagan RJ, Healy DP, de Cock P, Allegaert K, Sherwin C (2017). Dosing Optimization of Amikacin in Pediatric Patients with Burn Injuries and Those with Oncology Conditions. 101(S1),
  16. Huynh HQ, Illamola SM, Liu X, Bhakta Z, Sherwin CM, Liou TG, Carveth H, Young D (2017). Population pharmacokinetics of intravenous amikacin in adult cystic fibrosis patients. 52, S366-S366.
  17. Liu X, Smits A, Yu T, Wead S, Neely AN, Kagan RJ, Healy DP, Allegaert K, Sherwin C (2016). Amikacin pharmacokinetics in Pediatric patients with burn injuries compared to those with oncology conditions.
  18. Yu T, Rower JE, Liu X, Balch A, Halford Z, Korgenski EK, Sherwin C (2016). Development of a physiologically based Pharmacokinetic model of tacrolimus in adult organ transplant patients. 99, S71-S71.
  19. Constance JE, Stockmann C, Linakis M, Balch A, Korgenski EK, Spraker-Perlman H, Lemons R, Sherwin C (2016). Use of supportive care therapies among pediatric cancer patients with hematologic malignancies undergoing chemotherapy. 99, S90-S90.
  20. Rower JE, Liu X, Yu T, Mundorff M, Sherwin CM, Johnson (2016). Population pharmacokinetic modeling of magnesium sulfate for treatment of severe acute asthma in children in an emergency room setting. 99, S92-S93.
  21. Abdelaziz S, Yu T, Stockmann C, Sherwin CM, Constance JE, Balch (2016). Changes in pediatric prescribing patterns during Therapeutic drug monitoring of tacrolimus.
  22. Linakis MW, Cook SF, Rower JE, Rollins DE, Sherwin CM, Wilkins D (2016). Pharmacokinetics and renal clearance of beta-hydroxy-betamethylbutyrate in healthy adults.
  23. Enioutina EY, Balch A, Wilkes J, Olsen J, Thorell E, Pavia AT, Sherwin C (2016). IVIG use among children in freestanding children's hospitals in the United States.
  24. Liu X, Balch A, Dixon CL, Costantine MM, Sherwin C (2016). Logistic modeling of cord blood magnesium level and cerebral palsy incidence in children with maternal magnesium sulfate dosing.
  25. Liu X, Lieh-lai MW, Kauffman RE, Ward RM, Sherwin C (2016). Population pharmacokinetic modeling of morphine and Metabolites in 3-18 year-old children following surgery.
  26. Constance JE, Stockmann C, Linakis M, Balch A, Korgenski EK, Spraker-Perlman H, Lemons R, Sherwin C (2016). Use of supportive care therapies among pediatric cancer patients with hematologic malignancies undergoing chemotherapy.
  27. Wang Y, Liu X, Korgenski EK, Sherwin C (2016). Population pharmacokinetic modeling of gentamicin in pediatric patients and assessment of age influence.
  28. Liu X, Tak C, Sherwin CM, Shakib J (2016). Exploring maternal-infant linked influenza antibody kinetics using a unified population model.
  29. Wang Y, Liu X, Constance JE, Korgenski EK, Sherwin C (2016). Population pharmacokinetic modeling of gentamicin in children diagnosed with cancer.
  30. Sinha M, Yu T, Sherwin CM, Hillard MA, Spigarelli MG, Russell S (2015). Comparison of the Intradermal vs. Subcutaneous Delivery of Insulin and Glucagon in T1DM. 64, A276-A276.
  31. Yu T, Sinha M, Stockmann C, Hillard MA, Spigarelli MG, Russell SJ, Sherwin C (2015). Population pharmacokinetics of glucagon administered by subcutaneous or intradermal route in patients with type 1 diabetes. 37(8), e15.
  32. Liu X, Yu T, Dobson NR, McEntire BL, Ward RM, Spigarelli MG, Hunt CE, Sherwin C (2015). Pharmacokinetic modelling of plasma and salivary caffeine circulation in infants receiving extended caffeine therapy for intermittent hypoxia treatment. 42, S95-S96.
  33. Yu T, Sinha M, Hillard MA, Sherwin CM, Russell SJ, Spigarelli M (2015). Population Pharmacokinetics of Intradermal versus Subcutaneous Insulin Delivery in Patients with Type 1 Diabetes. 97, S48-S49.
  34. Roberts J, Beachy J, Yoder B, Ward R, Sherwin CM, Spigarelli MG, DiGeronimo R, Ohls R, Walsh W, Mayock D, Juul S, Christensen R, Baserga (2014). DANCE (Darbe administration in newborns undergoing cooling for encephalopathy): safety and pharmacokinetic trial. 62(1), 210-210.
  35. Yu T, Schoen K, Tak C, Clark EA, Varner MV, Spigarelli MG, Sherwin C (2014). Population Pharmacokinetics of Caffeine and Its Metabolites in Pregnant Women. 95, S94-S94.
  36. Firth SD, Yakub SY, Sherwin CM, Korgenski K, Constance JE, Stockmann C, Balch A, Spigarelli M (2014). Therapeutic Monitoring of Vancomycin in Children: Is There a Cost to Non-adherence of Guidelines?. 95, S56-S56.
  37. Constance JE, Balch A, Stockmann C, Sherwin CM, Spigarelli M (2014). Characteristics of Pediatric Cancer Patients Receiving Vancomycin. 95, S55-S55.
  38. Roberts JK, Sherwin CM, Beachy J, Ward RM, Baserga M, Spigarelli M (2014). Pharmacokinetics of Darbepoetin Alfa in the Treatment of Hypoxic-Ischemic Encephalopathy. 95, S99-S99.
  39. Balch AH, Thorell E, Constance J, Stockmann C, Korgenski K, Spigarelli MG, Sherwin C (2014). Factors Influencing Vancomycin Dose Reduction in Neonatal and Pediatric Patients. 95, S54-S55.
  40. Campbell SC, Stockmann C, Sherwin CM, Spigarelli M (2014). Examination of Gentamicin and Magnesium Sulfate Drug-Drug Interactions in Neonates.
  41. Bhongsatiern J, Sherwin CM, Stockmann C, Yu T, Reith DM, Desai PB, Spigarelli M (2014). An improved vancomycin dosing strategy in neonates using population pharmacokinetics and simulations to achieve pharmacodynamic target attainment.
  42. Kamyar M, Balch A, Campbell S, Robertson J, Sherwin CM, Clark EAS, Spigarelli MG, Rose (2014). The Evaluation of Teratogen Information Service Data as it Relates to Prenatal Care. 21(3), 254A-254A.
  43. Stockmann C, Hersh AL, Ampofo K, Byington CL, Sherwin CM, Spigarelli MG, Pavia A (2014). National Estimates of Pediatric Infectious Disease Hospitalizations from 1997-2009: An Analysis of the Kids¿ Inpatient Database. 1, S4-S4.
  44. Bridges ZM, Campbell SC, Thomas K, Sherwin CM, Spigarelli M (2013). Poison Control Center Calls Regarding Exposures to Pregnant and Breastfeeding Women. 35(5), 718-719.
  45. Yakub SY, Campbell SC, Sherwin CM, Constance J, Balch A, Spigarelli M (2013). Trends of use of vancomycin in neonates. 93, S49-S50.
  46. Campbell SC, Sherwin CM, Balch AH, Clark EA, Spigarelli M (2013). Examination of intrapartum use of magnesium sulfate and potential drug-drug interactions. 93, S20-S20.
  47. Fredrickson J, Balch A, Campbell SC, Sherwin CM, Clark EA, Spigarelli M (2013). Intrapartum use of magnesium sulfate and the relationship between maternal and neonatal magnesium blood levels. 93, S48-S49.
  48. Constance JE, Campbell SC, Linakis MW, Sherwin CM, Spigarelli M (2013). Dosing of vancomycin in neonates: on target for the therapeutic range?.
  49. Bhongsatiern J, C Stockmann C, Yu T, Spigarelli MG, Sherwin C (2013). Neonatal population pharmacokinetics and pharmacodynamics modeling of vancomycin to simulate target exposure attainment.
  50. Green A, Campbell SC, Thomas K, Sherwin CM, Spigarelli M (2013). Medication Exposures during Pregnancy and Breastfeeding. 35(5), 704-704.
  51. Constance JE, Balch A, Campbell SC, Stockmann C, Sherwin CM, Spigarelli M (2013). Frequency of achieving the therapeutic range with vancomycin in infants, children and adolescents. 35(5), 674-647.
  52. Bhongsatiern J, Stockmann C, Yu T, Reith DM, Sherwin CM, Desai P, Spigarelli M (2013). An External Evaluation of Vancomycin Pharmacokinetics Among Septic Neonates. 35(5), 664-664.
  53. Linakis MW, Constance J, Stockmann C, Campbell S, Sherwin CM, Spigarelli M (2013). Frequency of Vancomycin Target Trough Attainment for Cutaneous and Invasive Staphylococcal Infections. 35(5), 697-697.
  54. Campbell SC, McMillin G, Sherwin CM, Spigarelli M (2013). Thiopurine Methyltransferase Pharmacogenomic Testing: Known But Infrequently Done. 35(5), 714-715.
  55. Firth SD, Yakub SY, Sherwin CM, Constance JE, Balch A, Spigarelli M (2013). Therapeutic monitoring of Vancomycin in neonates: Is there a cost to non-adherence of guidelines?. 35(5), 681-681.
  56. Weston AS, Constance JE, Campbell SC, Stockmann C, Mihalopoulos NL, Sherwin CM, Spigarelli M (2013). Dosing Vancomycin in Pediatric Patients with Obesity. 35(5), 688-689.
  57. Stockmann C, Sherwin CM, Constance J, Campbell SC, Linakis M, Yu T, Balch A, Spigarelli M (2013). Paediatric Under Representation in Therapeutic Drug Monitoring Studies. 35(5), 674-675.
  58. Stockmann C, Sherwin CM, Spigarelli M (2013). Published Therapeutic Drug Monitoring Studies: Who Is Supporting Research?. 35(5), 706-706.
  59. Yu T, Stockmann C, Balch A, Sherwin CM, Spigarelli M (2013). Characteristics and Trends of Vancomycin Clinical Trials Registered in the United States from 1997-2012. 35(5), 716-716.
  60. Yu T, Sherwin CM, Balch A, Ward R, Spigarelli M (2013). Population pharmacokinetics of caffeine in neonates and infants to improve therapeutic range attainment. 35(5), 715-715.
  61. Firth SD, Yakub SY, Sherwin CM, Constance JE, Balch A, Spigarelli M (2013). Assessment of Therapeutic Guideline Adherence for Vancomycin Use in Neonates. 35(5), 700-700.
  62. Sherwin CM, Stockmann C, Zobell JT, McCrory B, Wisdom M, Young DC, Olson J, Ampofo K, Spigarelli M (2013). A Pharmacokinetic Evaluation of Tobramycin Administered One, Two, and Three Times Daily to Children with Cystic Fibrosis. 40, S131-S131.
  63. Stockmann C, Sherwin CM, Zobell JT, Lubsch L, Young DC, Olson J, Noyes BE, Ampofo K, Spigarelli M (2013). Population Pharmacokinetics of Vancomycin Used in the Treatment of Pediatric Cystic Fibrosis Pulmonary Exacerbations. 40, S132-S132.
  64. Jones BL, Sherwin CM, Neville KA, Spigarelli MG, Kearns GL, Leeder J (2012). Evidence of distinct histamine pharmacodynamic phenotypes in children. 91, S28.
  65. De Cock RFW, Allegaert K, Sherwin CM,de Hoog M, van den Anker JN, Danhof M, Knibbe CA (2012). Maturation of glomerular filtration rate in preterm and term neonates as reflected by clearance of amikacin, netilmicin and vancomycin. 91(Suppl. 1), S28.
  66. Zobell JT, Stockmann C, Young DC, Cash J, Sherwin CM, Spigarelli M, Chatfield BA, Ampofo (2011). Population pharmacokinetic (PK) and pharmacodynamic (PD) modeling of ticarcillin-clavulanate in pediatric CF patients. Suppl 34, 277.
  67. Saldana SN, Sherwin CM, Bies RR, Kuijvenhovem M, Aman M, Vinks A (2011). Population Pharmacokinetics of Risperidone Using Sparse and D-Optimal Sampling in Children and Adolescents. 89, S56-S57.
  68. De Cock RFW, Allegaert K, de Hoog M, Sherwin CM, Danhof M, Knibbe CA (2011). Predicting glomerular filtration rate using clearance of amikacin in neonates'Model Evaluation. 72(5), 846-847.
  69. Sagcal-Gironella AC, Sherwin CM, Tirona RG, Rieder MJ, Brunner HI, Vinks A (2011). Open-label, single dose pharmacokinetic study of prednisolone at steady state in young patients with SLE on prednisone therapy. 33(10), 1524.
  70. Sherwin CM, Sagcal-Gironella AC, Fukuda T, Brunner HI, Vinks A (2010). Development of a population pharmacokinetic model with enterohepatic recirculation for mycophenolic acid in patients with childhood systemic lupus erythmatosus (cSLE). 87, S61-S61.
  71. Sherwin CM, McCaffrey F, Broadbent RS, Reith DM and Medlicott N (2008). Investigation Into the Intravenous Delivery of Aminoglycoside Antibiotics to Extremely Premature Neonates.
  72. Medlicott NJ, Sherwin CM, Broadbent R, McCaffrey F, Reith D (2008). Intravenous Infusions of Gentamicin in Neonate Patients - Effects of Infusion Variables on Drug Administration Rates. 60(26 Suppl.), A11.

Commentary

  1. Enioutina EY, Job KM, Sherwin CM (2020). Why we need to pay attention to toxicity associated with herbal medicines. British journal of clinical pharmacology, 86(9), 1793-1794.

Editorial

  1. Sherwin CM, Lin Y (2023). Editorial: Women in obstetric and pediatric pharmacology: 2021. Frontiers in pharmacology, 14, 1191285.
  2. Sherwin CM,Lin Y (2023). Editorial: Women in obstetric and pediatric pharmacology: 2021. Frontiers in pharmacology, 14,
  3. Chen F, Tuzun F, Sherwin CM (2023). Editorial: Genetics and ontogeny in precision therapeutics for children. Frontiers in genetics, 14, 1308169.
  4. Sherwin C (2023). Editorial: Publishing in 2023 and Beyond. Current therapeutic research, clinical and experimental, 98, 100706.
  5. Job KM, Roberts JK, Sherwin C (2023). Editorial: Methods and protocols in obstetric and pediatric pharmacology: 2022. Frontiers in pharmacology, 14, 1205963.
  6. Sherwin C (2023). Editorial: Publishing in 2023 and Beyond. Current therapeutic research, clinical and experimental, 98,
  7. Job KM,Roberts JK,Sherwin C (2023). Editorial: Methods and protocols in obstetric and pediatric pharmacology: 2022. Frontiers in pharmacology, 14,
  8. Chen F,Tuzun F,Sherwin CM (2023). Editorial: Genetics and ontogeny in precision therapeutics for children. Frontiers in genetics, 14,
  9. Illamola, S.M., Birnbaum, A.K., Sherwin, C.M. (2019). Generic drug products in paediatrics: Where are the data? Br J Clin Pharmacol, 85(9), 1871-1873.
  10. Kumar, S.S., Biltaji, E., Bies, R., Sherwin, C.M. (2018). The clinical utility of pharmacometric models. Br J Clin Pharmacol, 84(7), 1413-1414.
  11. Biltaji, E., Kumar, S.S., Enioutina, E.Y., Sherwin, C.M. (2017). Can ad hoc analyses of clinical trials help personalize treatment decisions? Br J Clin Pharmacol, 83(11), 2337-2338.
  12. Biltaji, E., Kumar, S.S., Enioutina, E.Y., Sherwin, C.M.T. (2017). Can ad hoc analyses of clinical trials help personalize treatment decisions? Br J Clin Pharmacol, 83(11), 2337-2338.
  13. Ward, R.M., Sherwin, C.M. (2016). Newborns still lack drug data to guide therapy. Br J Clin Pharmacol, 82(6), 1410-1411.
  14. Allegaert K, Sherwin C (2016). Neonates and medicines: a roadmap to further improve neonatal pharmaceutical care. European journal of pediatrics,
  15. Allegaert K, Sherwin (2016). Neonates and medicines: a roadmap to further improve neonatal pharmaceutical care. European journal of pediatrics, 175(6), 743-6.
  16. Stockmann C, Constance JE, Roberts JK, Sherwin CM, Spigarelli M (2014). How Not to Be a Successful Clinical Pharmacologist. 2(2), 1027.

Letter

  1. Roberts, J.K., Linakis, M.W., Liu, X., Sherwin, C.M., van den Anker, J.N. (2018). Evident bias in a paracetamol metabolite population pharmacokinetic model applied to an external dataset [Letter to the editor]. Br J Clin Pharmacol.
  2. Roberts, J.K., Linakis, M.W., Liu, X., Sherwin, C.M.T., van den Anker, J.N. (2018). Evident bias in a paracetamol metabolite population pharmacokinetic model applied to an external dataset. [Letter to the editor]. Br J Clin Pharmacol, 84(7), 1628-1630.
  3. Stockmann C, Sherwin CM, Knackstedt ED, Hersh AL, Pavia AT, Spigarelli M (2016). Therapeutic Drug Monitoring of Ganciclovir Treatment for Cytomegalovirus Infections Among Immunocompromised Children. Journal of the Pediatric Infectious Diseases Society, 5(2), 231-232.
  4. Stockmann C,Sherwin CMT,Knackstedt ED,Hersh AL,Pavia AT,Spigarelli M (2016). Therapeutic drug monitoring of ganciclovir treatment for cytomegalovirus infections among immunocompromised children. Journal of the Pediatric Infectious Diseases Society, 5(2), 231-232.
  5. Stockmann C, Reilly CA, Fassl B, Gaedigk R, Nkoy F, Stone B, Roberts JK, Uchida DA, Leeder JS, Sherwin CM, Spigarelli MG, Yost GS, Ward R (2015). Effect of CYP3A5*3 on asthma control among children treated with inhaled beclomethasone. The Journal of allergy and clinical immunology, 136(2), 505-7.
  6. Stockmann C, Ross JS, Sherwin CM, Reilly CA, McDowell B, Fassl B, Nkoy F, Maloney CG, Spigarelli M (2014). Rate of asthma trial outcomes reporting on ClinicalTrials.gov and in the published literature. The Journal of allergy and clinical immunology, 134(6), 1443-1446.
  7. Stockmann C, Ross JS, Sherwin CMT, Reilly CA, McDowell B, Fassl B, Nkoy F, Maloney CG, Spigarelli M (2014). Rate of asthma trial outcomes reporting on ClinicalTrials.gov and in the published literature. The Journal of allergy and clinical immunology, 134(6), 1443-1446.
  8. Allegaert K, Sherwin C (2010). Amikacin in neonates: dosing recommendations should be based on both pharmacokinetics and dynamics. Singapore medical journal, 51(1), 88-9.
  9. Sherwin CM, Broadbent R, Medlicott NJ, Reith D (2009). Individualized Dosing of Amikacin in Neonates. European journal of clinical pharmacology, 65(12), 1267-1268.
  10. Sherwin CM, Broadbent RS, Medlicott NJ, Reith D (2009). Individualised dosing of amikacin in neonates. European journal of clinical pharmacology, 65(12), 1267-8.
  11. Sherwin CM, Svahn S, Broadbent RS, Van Der Linden A, Medlicott NJ, Reith D (2008). Netilmicin withdrawal: impact on neonates. The New Zealand medical journal, 121(1284), 95-7.

Abstract

  1. Biltaji E, Biskupiak JE, Sherwin CM, McMillin GA, Brixner D (2018). Optimizing the value of pharmacogenetic risk screening among patients with polypharmacy: A healthcare system experience.
  2. Karanam A, Sherwin CM, Birnbaum (2018). A PBPK model for modeling drug exposures of lamotrigine in breastfed infants.
  3. Kumar SS, Liu X, Illamola SM, Rashid J, Job K, Balch A, Rower J, Sherbotie J, Sherwin C (2018). Tacrolimus population pharmacokinetics in paediatric kidney transplant patients.
  4. Rashid R, Kumar SS, Sinha M, Hillard MA, Liu X, Russell SJ, Sherwin C (2018). Population pharmacokinetics of subcutaneously- and intradermally-administered glucagon in type 1 diabetic patients.
  5. Liu X, Smits A, Wang Y, Renard M, Wead S, Kagan RJ, Healy DP, De Cock P, Allegaert K, Sherwin C (2018). Disease condition affects amikacin pharmacokinetics and dosing in children.
  6. Becker S, Job K, Rower J, Forbes T, Sherwin CM, Nelson D, Johnson (2018). Pharmacokinetics of intravenous magnesium sulfate in status asthmaticus: A prospective cross-sectional analysis in a tertiary pediatric emergency department.
  7. Becker S, Forbes T, Job K, Rower J, Sherwin CM, Nelson D, Johnson (2018). Repeated Blood Samples for Measurement of Magnesium in Children with Severe Acute Asthma.
  8. Tak CR, Kim J, Gunning K, Ruble J, Sherwin CM, Nickman NA, Biskupiak (2018). Effect of a Prescription Order Requirement for Pharmacist-Administered Vaccination on Zoster Vaccination Rates.
  9. Liu X, Tak C, Sherwin CM, Shakib J (2017). A Semi-physiological Maternal-infant Model for Influenza Antibody Kinetics And The Impact Of Maternal Immunization Effects.
  10. Tak CR, Biltaji E, Kohlmann W, Maese L, Sherwin CM, Brixner D, Schiffman (2017). Cost-effectiveness of an early cancer surveillance strategy for patients with Li-Fraumeni Syndrome.
  11. Fateeva T, Krutivova N, Krepkova L, Job K, Bortnikova V, Sherwin CM, Enioutina (2017). Combating microbial resistance with phytodrugs.
  12. Biltaji E, Korgenski EK, Sherwin, CM Constance J (2017). Voriconazole therapeutic target attainment among pediatric patients.
  13. Enioutina EY, Wilkes J, Olson J, Thorell EA, Pavia AT, Sherwin CM, Balch A (2017). IVIG patterns among Pediatric patients with neoplasms admitted to U.S. Pediatric hospitals.
  14. Rower JE, Stockmann C, Molina KM.,Sherwin C (2017). Predicting Future Calcineurin Inhibitor Concentrations in Pediatric Transplant Recipients to Reduce Drug Monitoring Burden.
  15. Illamola SM, Young V, Job KM, Balch AH, Varner MW, Sherwin C (2017). Clinical management of antidepressants during pregnancy.
  16. Muhari-Stark E, Chen X, Sherwin CM, Wang Y, Wang J, Yao (2017). Association of meropenem clearance, covariates and estimated glomerular filtration rate in neonates.
  17. Rashid J, Vaughns JD, Williams EF, Liu X, van den Anker J, Sherwin C (2017). Population Pharmacokinetic Analysis of Enoxaparin in Obese Adolescents undergoing Bariatric Surgery.
  18. Kumar SS, Liu X, Kahanovitz L, Sherwin CM, Russell S (2017). Characterizing the absorption differences of insulin analogs using population pharmacokinetic analysis.
  19. Plumage EF, Illamola SM, Sherwin C (2017). Use of Mycophenolate Mofetil in Pediatric Patients Receiving Heart Transplants.
  20. Liu X, Wang Y, Sherwin C (2017). Developing physiologically based pharmacokinetic models that predict drug exposure of therapeutic monoclonal antibodies for rheumatoid arthritis treatment.
  21. Rattler TB Constance J, Sherwin C (2016). Polypharmacy Among Hospitalized Pediatric Patients with Type 1 Diabetes Mellitus.
  22. Ford TA, Constance JE, Sherwin C (2016). Type 1 Diabetes And The Risk Of Kidney Dysfunction Among Children Receiving Intravenous Antibiotics.
  23. Molina K, Rower J, Stockmann C, Sherwin C (2016). Predicting Tacrolimus Concentrations in Heart Transplant Recipients Using Population Pharmacokinetic Models.
  24. Balch A, Yu T, Constance JE, Sherbotie J, Rower J, Korgenski EK, Sherwin C (2016). Is Generic Tacrolimus Bioequivalent In Patients?.
  25. Caston R, Constance JE, Balch A, Korgenski EK, Sherwin C (2016). Vancomycin-associated nephrotoxicity among Pediatric patients with hematologic malignancy.
  26. Liu X, Tak C, Sherwin CM, Shakib J (2016). Population modeling of the influence of maternal influenza vaccination on infant immunity.
  27. Constance JE, Linakis MW, Stockmann C, Roberts JK, Sherwin CM, Spigarelli M (2015). Inpatient polypharmacy among children with leukemia or lymphoma receiving IV antibiotic therapy within the first year from diagnosis.
  28. Constance JE, Rower J, Stockmann C, Balch A, Sherwin CM, Spigarelli M (2015). IV anti-infective use in pediatric patients with cancer.
  29. Constance JE, Balch AH, Enioutina EY, Stockmann C, Linakis M, Sherwin CM, Spigarelli M (2015). Polypharmacy among hospitalized pediatric cancer patients.
  30. Prevedel JA, Constance JE, Sherwin CM, Spigarelli M (2015). Patterns of Tacrolimus Use in Pediatric Heart Transplant Recipient.
  31. Balch AH, Constance JE, Sherwin CM, Spigarelli M (2015). The Effect of tyrosine kinase inhibitors on pediatric growth.
  32. Enioutina EY, Constance JE, Balch AH, Sherwin CM, Spigarelli M (2015). Vaccination patterns among pediatric cancer patients treated with vancomycin.
  33. Bhongsatiern J, Stockmann C, Yu T, Moorthy G, Constance JE, Spigarelli MG, Desai PB, Sherwin C (2015). Renal function descriptors in neonates: Which creatinine-based equation best describes vancomycin clearance?.
  34. Schiffman JD, Kirchhoff AC, Spigarelli MG, Kaul S, Smits-Seemann R, Sherwin CM, Constance JE, Brenna Eldridge B, Fluchel M, Christenson CP, Garfield K, Mason CC, Korgenski EK. Knackstedt ED, Blaschke A, Raetz EA, Lemons RS, Clark E (2015). Building a comprehensive, value-based resource for childhood cancer in Utah.
  35. Constance JE, Linakis MW, Balch AH, Sherwin CM, Spigarelli M (2015). Inpatient polypharmacy among children with leukemia or lymphoma receiving IV antibiotic therapy within the first year from diagnosis.
  36. Stockmann C, Hersh AL, Sherwin CM, Spigarelli MG, Frymoyer (2015). Targeting Vancomycin AUC in Neonates - A Model Based Bayesian Approach for Personalized Therapeutic Drug Monitoring.
  37. Constance JE, Ward RM, Sherwin CM, Korgenski K, Spigarelli M (2015). Nonsteroidal anti-inflammatory drug-associated nephrotoxicity among neonates diagnosed with patent ductus arteriosus.
  38. Balch A, Green T, Hansen C, Sherwin C (2015). Practical Issues in Calculating Sample Size for Ordinal Data with Repeated Measures.
  39. Balch AH, Constance JE, Sherwin CM, Spigarelli M (2015). A Retrospective Study of Kidney Injury vs Vancomycin Use by Age.
  40. Linakis MW, Sherwin CM, Roberts JK, Spigarelli MG, Wilkins D (2015). Population pharmacokinetics of nicotine delivered from a transdermal matrix patch.
  41. Yu T, Liu X, Balch AH, Molina KM, Constance JE, Prevedel JA, Korgenski EK, Spigarelli MG, Sherwin C (2015). Population pharmacokinetics of tacrolimus in pediatric heart transplant patients.
  42. Liu X, Yu T, Balch AH, Sherbotie J, Korgenski EK, Spigarelli MG, Sherwin C (2015). Population Pharmacokinetics of Tacrolimus in Pediatric Patients with Kidney Transplant.
  43. Constance JE, Campbell SC, Stockmann C, Balch AH, Korgenski EK, Sherwin CM, Spigarelli M (2014). Incidence of acute kidney injury among vancomycin-treated children with hematologic malignancies.
  44. Bhongsatiern J, Sherwin CM, Yu T, Stockmann C, Allegaert K, Knibbe CAJ, Reith DM, Desai PB, Spigarelli M (2014). Development of Vancomycin Dosing Recommendations in Preterm and Term Neonates using Population Pharmacokinetic Modeling and Simulation.
  45. Stockmann C, Sherwin CM, Spigarelli M (2014). zscore ¿ An R Package for Deriving Weight and Height for Age Z Scores and Exact Percentiles from Birth to 20 Years of Age.
  46. Roberts JK, Ward RM, Beachy J, Baserga M, Spigarelli MG, Sherwin C (2014). Population pharmacokinetics of darbepoetin alfa for the treatment of neonatal hypoxic-ischemic encephalopathy.
  47. Campbell SC, Johnson-Davis KL, Linakis MW, McMillin GA, Sherwin CM, Spigarelli M (2014). Evaluating the Relationship of Age and Thiopurine Metabolites in Pediatrics.
  48. Linakis MW, Stockmann C, Campbell SC, Williams RV, Burch PT, Lambert LM, Sherwin CM, Reilly CA, Spigarelli M (2014). A Novel Sensitive and Specific Liquid Chromatography-Tandem Mass Spectrometry (LC-MS-MS) Method for the Quantification of Oxandrolone in Human Plasma.
  49. Sneddon JR, Campbell SC, Balch AH, Sherwin CM, Spigarelli M (2014). Trends of KRAS Pharmacogenomic Testing for Cetuximab and Panitumumab.
  50. Constance JE, Sherwin CM, Korgenski EK. Spigarelli M (2014). Intravenous meropenem use among pediatric patients with and without cancer.
  51. Yu T, Stockmann C, Constance JE, Korgenski EK, Spigarelli MG, Sherwin C (2014). Population Pharmacokinetics and Dosing Regimen Optimization of Intravenous Vancomycin in Infants.
  52. Clements N, Constance JE, Yu T, Campbell SC, Linakis M, Sherwin CM, Spigarelli M (2014). Therapeutic drug monitoring and target vancomycin attainment among pediatric patients undergoing hemodialysis.
  53. Roberts JK, Sherwin CM, Beachy J, Ward RM, Baserga M, Spigarelli M (2014). Pharmacokinetics of Darbepoetin Alfa in the Treatment of Hypoxic-Ischemic Encephalopathy. Encore,
  54. Yu T, Balch AH, Spigarelli MG, Sherwin C (2014). Population Pharmacokinetics/Pharmacodynamics of Intravenous Vancomycin in Adolescent Patients.
  55. Campbell SC, Johnson-Davis K, Linakis MW, Roberts JK, McMillin GA, Sherwin CM, Spigarelli M (2014). Evaluating the Relationship of Age and Thiopurine Methyltransferase Activity.
  56. Campbell SC, Johnson-Davis K, McMillin GA, Sherwin CM, Spigarelli M (2014). Trends of Pediatric and Adolescent TPMT Pharmacogenomic Testing.
  57. Stockmann C, Hersh AL, Pavia AT, Byington CL, Blaschke AJ, Sherwin CM, Spigarelli MG, Ampofo (2014). National Trends in Pediatric Pyogenic Arthritis and Osteomyelitis, 1997 ¿ 2009.
  58. De Cock RFW, Allegaert K, Brussee J, Sherwin CM, Mulla H, de Hoog M, van den Anker JN, Danhof M, Knibbe CA (2014). Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration.
  59. Constance JE, Balch AH, Sherwin CM, Spigarelli M (2014). Patterns of Gentamicin Use Among Pediatric Cancer Patients.
  60. Linakis MW, Campbell SC, Stockmann C, Johnson-Davis KL, McMillin GA, Sherwin CM, Spigarelli M (2014). Regional Differences in Thiopurine Methyltransferase Activity.
  61. Han H, Constance JE, Sherwin CM, Korgenski EK, Spigarelli M (2014). Evaluation of disparities in achieving therapeutic recommendations among pediatric patients receiving gentamicin.
  62. Linakis MW, Campbell SC, Stockmann C, Johnson-Davis KL, McMillin GA, Balch AH, Sherwin CM, Spigarelli M (2014). Frequency of Thiopurine Metabolite Tests with Clinically-Important Results Requiring Modifications to Therapy.
  63. Balch AH, Constance JE, Sherwin CM, Spigarelli M (2014). Pediatric Cancer Patients Receiving Gentamicin and Vancomycin Receive Higher Doses and More Combination Therapy.
  64. Baserga M, Beachy J, Yoder BA, Ward RM, Roberts JK, Sherwin CM, Spigarelli MG, DiGeronimo R, Ohls R, Walsh W, Mayock D, Juul SE, Christensen (2014). DANCE (Darbe Administration in Newborns Undergoing Cooling for Encephalopathy: Safety and Pharmacokinetic Trial. American Academy of Pediatrics.
  65. Yu T, Campbell SC, Stockmann C, Clark EAS, Varner MW, Spigarelli MG, Sherwin C (2014). Pharmacokinetic Changes of Caffeine during Pregnancy and Simulation of Pregnant Population.
  66. Cook SF, Sherwin CM, Williams EF, Roberts JK, King AD, Deutsch N, Samiee-Zafarghandy S, Mankala S, Wilkins DG, van den Anker J (2014). Population pharmacokinetics of intravenous acetaminophen in preterm and term neonates.
  67. Spigarelli MG, Healy D, Buterbaugh W, Gottschlich MM, Kagan R, Sherwin C (2013). Rapid Repeat Dosing of Zolpidem - Apparent Kinetic Change Between Doses.
  68. Sherwin CM, Jones B, Leeder JS, Neville KA, Kearns GL, Spigarelli M (2013). Dense Data - Methods to Handle Massive Data Sets without Compromise.
  69. Constance J, Durbano D, Campbell SC, Sherwin CM, Balch A, Spigarelli M (2013). Nephrotoxicity Associated with Vancomycin Use in a Neonatal Population.
  70. Balch A, Stockmann C, Constance J, Yu T, Campbell SC, Sherwin CM, Spigarelli M (2013). Therapeutic Monitoring of Vancomycin Concentrations and Healthcare Provider Response to High and Low Troughs.
  71. Linakis M, Constance J, Bailey S, Stockmann C, Campbell SC, Balch A, Sherwin CM, Spigarelli M (2013). Role of MRSA and Coagulase-Negative Staphylococcus Bacteremia in the Increasing Use of Vancomycin.http://www.healio.com/pediatrics/emerging-diseases/news/online/%7B323e9862-f13f-4310-bf57-13da6a267ab1%7D/vancomycin-use-increased-despite-modest-increase-in-mrsa-and-coagulase-negative-staphylococcus.
  72. Yakub SY, Campbell SC, Sherwin CM, Constance J, Balch A, Spigarelli M (2013). Prolonged Vancomycin Use in a Pediatric Population.
  73. Campbell SC, McMillin GA, Sherwin CM, Spigarelli, M (2013). Thiopurine Methyltransferase Pharmacogenomic Test Utilication in Pediatrics.
  74. Sherwin CM, Wead S, Stockmann CR, Healy D, Spigarelli MG, Neely, (2013). Amikacin Population Pharmacokinetics Associated with Pediatric Burn Patients.
  75. Campbell SC, McMillin GA, Sherwin CM, Spigarelli M (2013). Pharmacogenomic Testing Trends in Adolescents.
  76. Green AA, Campbell SC, Sherwin CM, McMillin GA, Spigarelli M (2013). Pharmacogenomic Testing Trends in Pediatric Patients.
  77. Stockmann C, Sherwin CM, Campbell SC, Linakis M, Constance J, Balch A, Spigarelli M (2013). Characteristics of Maternal-Fetal Pharmacology Studies Registered in the United States through ClinicalTrials.gov.
  78. Sherwin CM, Constance JE, Spigarelli M (2013). Comparison of Serum Vancomycin Concentrations in a Paediatric Population pre- and post- 2009 IDSA Guideline Recommendations.
  79. Sherwin CM, Stockmann C, Healy D, Buterbaugh W, Gottschlich MM, Spigarelli MG, Kagan (2013). Population Pharmacokinetics of Zolpidem among Children with Severe Burn Injuries.
  80. Yu T, Sherwin CM, Stockmann C, Spigarelli M (2013). Evolution of Vancomycin Clinical Trials and Development of New Antibiotic Therapies for Resistant Gram-Positive Bacterial Infections in the United States from 1999 to 2012.
  81. Schoen K, Constance J, Sherwin CM, Ward R, Spigarelli M (2013). Determination of Vancomycin Induced Nephrotoxicity in Neonates with Patent Ductus Arteriosus.
  82. Firth SD, Yakub SY, Sherwin CM, Korgenski K, Constance JE, Stockmann C, Balch A, Spigarelli M (2013). Therapeutic Monitoring of Vancomycin in Children: Is There a Cost to Non-adherence of Guidelines?.
  83. Firth SD, Yakub SY, Sherwin CM, Korgenski K, Constance JE, Stockmann C, Balch A, Spigarelli M (2013). Assessment of Guideline Adherence for Pediatric Vancomycin Use.
  84. Campbell SC, Linakis MW, Tak CR, McMillin G, Sherwin CM, Spigarelli M (2013). Clinical Utilization of Pharmacogenomic Testing: What is it for Drugs with Strong Recommendations?.
  85. Constance JE, Balch A, Campbell SC, Stockmann C, Sherwin CM, Spigarelli M (2013). Nephrotoxicity associated with vancomycin use in a pediatric population.
  86. Yu T, Stockmann C, Sherwin CM, Olson J, Healy D, Spigarelli M (2013). Determination of an Optimal Amikacin Dosing Regimen for Pediatric Burn Patients.
  87. Bhongsatiern J, Sherwin CM, Stockmann C, Yu T, Reith DM, Desai PB Spigarelli M (2013). Use of Monte Carlo Simulation to Evaluate Vancomycin Dosing Regimens in Neonates.
  88. Doll E, Wilkes J, Sherwin CM, Srivastava R, Faix R, Spigarelli MG, Clark EAS, Bonkowsky (2013). Neonatal Magnesium Levels Correlate with Improved Neurological Outcomes in Premature Infants.
  89. Dowse B, Campbell S, Sherwin CM, Spigarelli (2012). Trends in use and monitoring of vancomyin in pediatric patients.
  90. Burch P, Minich LL, Spigarelli M, Lambert L, Sherwin CM, Williams R (2012). Use of Oxandrolone to Promote Growth In Neonates with Complex Congenital Heart Disease: An Open-Label Pilot Trial.
  91. Campbell SC, Sherwin CM, McMillin GA, Spigarelli (2012). Understanding the Use and Trends of Pharmacogenomic Testing.
  92. De Cock RFW, Allegaert K, Sherwin CM, de Hoog M, van den Anker, JN, Danhof M, Knibbe CA (2011). Maturation of GFR in preterm and term neonates reflected by clearance of different antibiotics.
  93. Saldana SN, Sherwin CM, Kuijvenhovem M, Aman, M, Vinks A (2010). Population Pharmacokinetics of Risperidone Using Sparse and D-Optimal Sampling in Children and Adolescents. Encore,
  94. Reith DM, Owens K, Svahn S, Boradbent RS, Medlicott NJ, Sherwin C (2009). Pharmacokinetic Pharmacodynamic study of hearing impairment in neonates treated with aminoglycosides using a logistic regression model. 105(Suppl 1), 131.
  95. Broadbent, R., Sherwin, C.M., Kostan, E., Medlicott, N.J., Reith, D.M. (2008). The Effect Upon Volume of Distribution of Intravenous Volume Expanders Delivered to Neonates Treated with Gentamicin for Suspected Sepsis. Proceedings of the 2nd Congress of the European Academy of Pediatrics; Nice, France [Abstract]. Arch Dis Child, 93(Supplement 2), espnic31.
  96. Owens K, Sherwin CM, Reith DM, Medlicott N (2008). Evaluating Gentamicin and Ototoxicity in Neonates to Optimize Development of a New Dosing Regimen. The New Zealand medical journal, 121(1274),
  97. Sherwin CM, Medlicott NJ, Broadbent RS, Reith D (2008). Simulation and development of a netilmicin extended dosing regimen for extremely premature neonates.
  98. Owen K, Sherwin CM, Medlicott NJ, Reith D.M (2008). Evaluating Gentamicin and Ototoxicity in Neonates to Optimize Development of a New Dosing Regimen.
  99. Owens K, Sherwin CM, Medlicott NJ, Reith D (2008). Investigation of Hearing Impairment in Neonates Treated with Aminoglycosides.
  100. Sherwin CM, Svahn S, Medlicott NJ, Broadbent RS, Reith D (2008). Pharmacodynamic analysis of hearing impaired neonates treated with amikacin.
  101. Sherwin CM, Svahn S, Van der Linden AJ, Medlicott NJ, Broadbent RS, Reith D (2008). Simulation of an optimal pharmacokinetic and pharmacodynamic amikacin dosing regimen for neonates.
  102. McCaffrey F, Sherwin CM, Broadbent R, Reith DM, Medlicott N (2008). What's in Delivery?.
  103. Sherwin CM, Svahn S, Van der Linden AJ, Medlicott NJ, Broadbent RS, Reith D (2007). A Pharmacokinetic/Pharmacodynamic Model to Determine Optimal Dosing Targets for Amikacin in Neonatal Sepisis.
  104. Broadbent R, Sherwin CM, Young S, Worth J, McCaffrey F, Medlicott NJ, et al (2007). Utility of IL-12 and IL-10 in Comparison with Other Cytokines and Acute Phase Reactants in teh Initial workup of Suspected Neonatal Sepsis.
  105. Broadbent R, Sherwin CM, Young S, Worth J, McCaffrey F, Medlicott NJ, et al (2007). Utility of IL-12 and IL-10 in Comparison with Other Cytokines and Acute Phase Reactants on Day Three of Suspected Neonatal Sepsis.
  106. Sherwin CM, Kostan E, Medlicott NJ, Broadbent RS, Reith D (2007). The Effect Upon V of IV Volume Expanders Delivered to Neonates Treated with Gentamicin for Suspected Sepsis.
  107. Sherwin CM, Svahn S, Medlicott NJ, Broadbent RS, Reith D (2006). Population pharmacokinetics of amikacin in extremely low birth weight to term neonates.
  108. Sherwin CM, Broadbent RS, Reith D (2006). A Pilot Study of Cytokines as Indicators of Pharmacokinetic Change for Gentamicin in Septic Neonates.
  109. Reith DM, Sherwin CM, Svahn S, Medlicott NJ, Broadbent (2006). Netilmicin to Amikacin in Neonates...Was the Change Good?.
  110. Sherwin CM, Svahn S, Medlicott NJ, Broadbent RS and Reith D (2006). Netilmicin to Amikacin in Neonates...Was the Change Good.
  111. Sherwin CM, Broadbent RS and Reith D (2005). Evaluation of the pharmacokinetics of netilmicin in neonates with suspected or proven sepsis.
  112. Balch AH, Wilkes J, Olson J, Thorell EA, Pavia AT, Sherwin CM, Enioutina E IVIG use in pediatric cancer patients.

Other

  1. Rahimi R, Hashemi Rafsanjani SMR, Heidari-Soureshjani S, Sherwin CM, Kasiri (2024). The Association between Use of Renin-Angiotensin-Aldosterone System Inhibitors and the Risk and Mortality of Pancreatic Cancer: A Systematic Review and Meta-Analysis. Current reviews in clinical and experimental pharmacology,
  2. Darvishi M, Amiri MM, Heidari-Soureshjani S, Sherwin CM, Mardani-Nafchi (2023). The Association between Statins Intake and Risk of Post Stroke Pneumonia: A Systematic Review and Meta-analysis. Current reviews in clinical and experimental pharmacology,
  3. Anbari K, Amiri MM, Heidari-Soureshjani S, Sherwin CM, Kasiri (2023). A Systematic Review and Meta-analysis on the Role of Statins in the Prevention of Mortality Following Pancreatic Cancer. Anti-cancer agents in medicinal chemistry,
  4. Maharaj AR, Wu H, Zimmerman KO, Autmizguine J, Kalra R, Al-Uzri A, Sherwin CMT, Goldstein SL, Watt K, Erinjeri J, Payne EH, Cohen-Wolkowiez M, Hornik C (2021). Population pharmacokinetics of olanzapine in children. British journal of clinical pharmacology, 87(2), 542-554.
  5. Smit C, Goulooze SC, Brüggemann RJM, Sherwin CM, Knibbe CA (2021). Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1-18 Years. The AAPS journal, 23(3), 53.
  6. Zhang Y, Sherwin CM, Gonzalez D, Zhang Q, Khurana M, Fisher J, Burckart GJ, Wang Y, Yao LP, Ganley CJ, Wang (2021). Creatinine-Based Renal Function Assessment in Pediatric Drug Development: An Analysis Using Clinical Data for Renally Eliminated Drugs. Clinical pharmacology and therapeutics, 109(1), 263-269.

Video/Film/CD/Web/Podcast

  1. Biltaji E, Biskupiak J, Sherwin CM, McMillin G, Brixner (2018). The Value of Using Pharmacogenetic Risk Scores in Routine Practice.
  2. Sherwin CM, Craig D, Yellepeddi V, Rosenthal L, Morris M (2018). 9 Times Ibuprofen Won't Work'and Could Be Dangerous by Joanna Chen.
  3. Sherwin C (2017). Giving newborns medicine is a dangerous guessing game. Can we make it safer?.
  4. Ward RM, Sherwin C (2017). Making Medications Safer for Newborns.
  5. Davis J, Rousseau R, Sherwin CM, Laughon (2017). Here's how to make traditional medicines safer for newborns.